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Summary
Background The epidemiology of Chlamydia trachomatis in the Middle East and north Africa is poorly understood. We 
aimed to provide a comprehensive epidemiological assessment of C trachomatis infection in the Middle East and 
north Africa.
Methods We did a systematic review of C trachomatis infection as well as a meta-analysis and meta-regression of 
C trachomatis prevalence. We searched PubMed and Embase, as well as regional and national databases up to 
March 13, 2019, using broad search terms with no language or year restrictions. Any document or report including 
biological measures for C trachomatis prevalence or incidence was eligible for inclusion. We extracted all measures of 
current (genital or rectal), recent, and ever infection with C trachomatis. We estimated pooled average prevalence in 
different populations using random-effects meta-analysis. Factors associated with prevalence and sources of between-
study heterogeneity were determined using meta-regression.
Findings We identified a total of 1531 citations, of which 255 reports contributed to 552 C trachomatis prevalence 
measures from 20 countries. No incidence measures were identified. Pooled prevalence of current genital infection 
was 3·0% (95% CI 2·3–3·8) in general populations, 2·8% (1·0–5·2) in intermediate-risk populations, 13·2% (7·2–20·7) 
in female sex workers, 11·3% (9·0–13·7) in infertility clinic attendees, 12·4% (7·9–17·7) in women with miscarriage, 
12·4% (9·4–15·7) in symptomatic women, and 17·4% (12·5–22·8) in symptomatic men. Pooled prevalence of current 
rectal infection was 7·7% (4·2–12·0) in men who have sex with men. Substantial between-study heterogeneity was 
found. Multivariable meta-regression explained 29·0% of variation. Population type was most strongly associated with 
prevalence. Additional associations were found with assay type, sample size, country, and sex, but not with sampling 
methodology or response rate (about 90% of studies used convenience sampling and >75% had unclear response rate). 
There was no evidence for temporal variation in prevalence between 1982 and 2018.
Interpretation C trachomatis prevalence in the Middle East and north Africa is similar to other regions, but higher 
than expected given its sexually conservative norms. High prevalence in infertility clinic attendees and in women with 
miscarriage suggests a potential role for C trachomatis in poor reproductive health outcomes in this region.
Funding National Priorities Research Program from the Qatar National Research Fund (a member of Qatar Foundation).
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
With more than 100 million incident infections every year,1 
Chlamydia trachomatis is one of the most common sex­
ually transmitted infections (STIs) worldwide.2,3 Although 
curable, control and early detection of C trachomatis 
infection are challenged by its largely asymptomatic 
nature.4 Untreated C trachomatis infection is associated 
with serious reproductive tract conditions including pelvic 
inflam ma tory disease, ectopic pregnancy, infertility among 
women, and epididymitis among men.5,6
Despite burdensome sequelae, STI control has long 
languished on health policy agendas. The 2030 Agenda 
on Sustainable Development7 aims to remedy this 
situation and led to WHO’s Global Health Sector Strategy 
on STIs.8 The strategy proposes an integrated approach 
for STI prevention and control that addresses core 
Sustainable Development Goals, mainly through securing 
universal access to sexual and reproductive health­care 
services and rights.7,8 The first strategic direction of this 
STI Strategy is “the need to understand the sexually 
transmitted infect ion epidemic and response as a basis 
for advocacy, pol itical commitment, national planning, 
resource mobiliza tion and alloca tion, implementation, 
and programme improvement.”8
The epidemiology of STIs, including C trachomatis, 
remains poorly understood in the Middle East and north 
Africa—a region comprising 10% of the world’s popula­
tion.9–11 Here, political and sociocultural sensitivities have 
set STIs low on countries’ public health agendas, resulting 
in limited capacity for surveillance and programmes 
targeting sexual health, despite the possibility of a hidden 
disease burden.9 For example, the prevalence of primary 
infertility in the Middle East and north Africa, based on 
demographic and reproductive health surveys, has been 
Articles
e1198 www.thelancet.com/lancetgh   Vol 7   September 2019
estimated to be the highest worldwide (although that of 
secondary infertility seems to be the lowest).12 Still, the 
con tribution of C trachomatis, or other STIs, to this dis ease 
burden remains unknown. Against this background, our 
study aimed to characterise C trachomatis epidemiology in 
the Middle East and north Africa.
Methods
Search strategy and selection criteria
We did a systematic review as well as a meta­analysis 
and meta­regression. We followed systematic review 
methods proposed by the Cochrane Collaboration,13 and 
report findings following the Preferred Reporting Items 
for Systematic Reviews and Meta­analyses guide lines14 
(appendix pp 5–6). We did exhaustive searches using 
PubMed and Embase, regional and national databases 
(WHO Index Medicus for the Eastern Mediterranean 
region, Iraqi Academic Scientific Journals data base, 
and Iranian Scientific Information Database), abstract 
archives of International AIDS Society Confer ences,15 as 
well as country­level and international organisa tions’ 
reports available through the Middle East and North Africa 
HIV/AIDS Epidemiology Synthesis Project database.10,11
Our searches were done up to March 13, 2019, using 
broad search terms (MeSH/Emtree terms exploded to 
cover all subheadings and free­text terms) with no language 
or year restrictions. The appendix (p 7) summarises the 
search criteria and search terms used. The Middle East and 
north Africa were defined as 23 countries extending from 
Morocco in the west to Pakistan in the east (appendix p 8). 
This definition for the Middle East and north Africa 
follows earlier convention applied in HIV and hepatitis C 
research,10,16–22 and is based on definitions by WHO, 
UNAIDS, and the World Bank.
Search results were checked for duplicates using 
Endnote (version 8.2). We screened titles and abstracts of 
unique citat ions. Full texts of citations deemed relevant or 
potentially relevant were retrieved for further screening 
by AS and HC. Any document or report including 
biological meas ures for C trachomatis prevalence or 
incidence, or both, based on primary data was eligible for 
inclusion. Case reports, case series, editorials, commen­
taries, reviews, and reports about military personnel 
stationed in the Middle East and north Africa, but not 
from these countries, were excluded. Reference lists of 
literature reviews and all relevant articles were hand­
searched for additional eligible reports.
In this Article, the term report refers to a document 
(article, conference abstract, or country­level report) 
containing outcome measures of interest (ie, prevalence 
or incidence) for one or more populations, and the term 
study refers to details of a specific outcome measure in 
a specific population. Consequently, one report could 
contribute multiple studies and one study could be 
published in different reports. Duplicate study results 
were included only once using the most detailed report.
Data analysis
Data from relevant reports were extracted by AS with 
input from LJA­R. Independent extraction was done by 
Research in context
Evidence before this study
In a context of continuing stigma and political and sociocultural 
sensitivities, the Middle East and north Africa region has a 
dearth of epidemiological data about sexually transmitted 
infections. The prevalence of Chlamydia trachomatis and its 
distribution among populations at differing levels of risk of 
exposure remain largely unknown. A PubMed search using the 
search criteria (“Chlamydia”[MeSH] AND “Review” [Publication 
Type]) identified no systematic review and meta-analysis of 
regional scope for all subpopulations for this infection in the 
Middle East and north Africa or elsewhere.
Added value of this study
Using rigorous state-of-the-art methodologies with current 
empirical evidence, this study provided the first comprehensive 
epidemiological assessment of C trachomatis infection in the 
Middle East and north Africa. The study searched diverse 
sources of data, beyond international electronic databases, 
and identified a large volume of published and unpublished 
data, some of which now appears in the literature for the first 
time. The scope of evidence allowed analyses that found 
revealing associations relevant for the Middle East and north 
Africa and elsewhere. Unexpectedly, given this region’s sexually 
conservative norms, the study estimated a C trachomatis 
prevalence of 3% in the population at large, similar to estimates 
from other regions. The study also documented high 
C trachomatis prevalence levels in infertility clinic attendees and 
in women with miscarriage, with odds of infection three-times 
higher than in the general population.
Implications of all the available evidence
There is a substantial C trachomatis infection and disease burden 
in the Middle East and north Africa that is neglected and poorly 
recognised despite its social and economic toll in a region 
comprising 10% of the world’s population. C trachomatis 
infection appears to be consistently associated with infertility 
and poor reproductive health outcomes in this region, yet these 
conditions are not linked to the possibility of an underlying 
infectious cause. The Middle East and north Africa is far from 
achieving WHO’s Global Health Sector Strategy on Sexually 
Transmitted Infections, 2016–21. The findings of this study 
provide a scientific foundation to develop an evidence-informed 
public health response against C trachomatis and its burdensome 
sequelae. The challenge will be to implement effective targeted, 
culturally appropriate, and gender-specific programmes to tackle 
C trachomatis infection and improve sexual health in general.
See Online for appendix
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HC, and discrepancies were settled by consensus, or by 
contacting authors. Data from non­English articles were 
extracted from the full text by native speakers.
We extracted all measures of current (genital or rectal), 
recent, and ever infection with C trachomatis. We stratified 
data according to the study population’s risk of exposure 
to C trachomatis or clinical manifestations (panel). Popula­
tions were defined as per original study authors’ specific 
population definition and inclusion criteria (such as for 
infertile populations or women with miscarriage). We 
classified women and men as symptomatic only if there 
was an indication for the presence of C trachomatis­related 
signs and symptoms. We subsequently synthesised data 
by type of assay used for C trachomatis detection and 
summarised these data using medians and ranges.
Studies applying the same assay to different biological 
specimens were included only once, based on a sequential 
order that prioritised, for women, C trachomatis detection 
in endocervical swabs, followed by vaginal and urine 
samples; and for men, detection in urethral swabs, 
followed by urine and semen samples. Studies applying 
nucleic acid amplification test (NAAT) and culture to the 
same biological specimen were included separately given 
our interest in studying their contribution to hetero­
geneity in C trachomatis prevalence, and in generating 
STI­estimation correction factors based on assay type.23–25 
Studies applying other antigen detection assays to the 
same biological specimen were included only once based 
on assay sensitivity (direct fluorescence and enzyme­
linked immunoassays on genital samples were prioritised 
over Giemsa staining).
We excluded studies using tissue specimens from the 
upper genital tract, or including less than ten participants. 
We stratified the analyses by sex where relevant. Studies 
reporting only an overall measure for men and women 
were classified according to the predominant sex in the 
sample.
We did risk of bias and precision assessments. Informed 
by the Cochrane approach,13 we classified studies as having 
low versus high risk of bias for each of three quality 
domains assessing rigour of sampling methodology 
(prob ability based vs non­probability based), type of 
C trachomatis ascertainment (biological assay vs other, 
such as self­report), and response rate (≥80% response rate 
or ≥80% of target sample size reached [the latter for studies 
using respondent­driven sampling] vs <80%). Studies with 
unavail able information about any given domain were 
classified as having unclear risk of bias for that domain. 
Studies were considered of higher precision if 200 partici­
pants or more underwent testing for C trachomatis, which 
was judged as an acceptable level of precision assuming a 
mean prevalence of 3% in the general population.
We produced forest plots to visualise estimates of 
prevalence and 95% CIs for each at­risk population, 
stratified by type of assay. Pooled average prevalence and 
95% CIs were then estimated using meta­analysis for 
each stratum. A Freeman­Tukey type arcsine square­root 
transfor mation was first applied to stabilise variances of 
prevalence measures.26,27 Measures were then weighted 
using the inverse­variance method,27,28 before being pooled 
using a DerSimonian­Laird random­effects model.29 This 
model assumes a normal distribution for true effect sizes 
(ie, prevalence) across studies, which factors in sampling 
variation and true between­study heterogeneity.30
We did heterogeneity assessment using Cochran’s 
Q statistic to confirm existence of heterogeneity across 
studies, I² to quantify magnitude of between­study vari­
ation that is due to true differences in effect size rather 
than chance, and prediction interval to estimate the 
95% CI of the distribution of true effect sizes.30,31 We did 
subgroup meta­analyses whenever five studies or more 
were available, using the R software (version 3.4.2).32
We did random­effects meta­regression analyses to 
identify sources of between­study heterogeneity and 
estimated the magnitude of their association with preva­
lence. We included risk of bias and precision domains 
in the meta­regression analyses. We considered the 
Panel: Definitions for at-risk population classification
General populations (populations at low risk)
Populations at low risk of exposure to Chlamydia trachomatis infection such as antenatal 
clinic attendees, blood donors, and pregnant women.
Populations at intermediate risk
Populations who presumably might have some sexual contacts with populations 
engaging in high sexual risk behaviour, and have therefore a higher risk of exposure to 
C trachomatis than the general population. These populations comprise prisoners, people 
who inject drugs, truck drivers, migrant workers, and HIV-infected individuals in a setting 
where the HIV epidemic is driven by injecting drug use.
Populations at high risk
Populations at high risk of exposure to C trachomatis as a consequence of specific high 
sexual risk behaviours such as female sex workers, men who have sex with men, male sex 
workers, men-to-women transgenders, and HIV-infected individuals in a setting where 
the HIV epidemic is driven by sexual transmission.
Infertility clinic attendees
Infertile women or men and their partners were included in a separate category given the 
potential biological link between C trachomatis infection and infertility.
Women with miscarriage
These women were included in a separate category given the potential biological link 
between C trachomatis infection and miscarriage.
Women with ectopic pregnancy
These women were included in a separate category given the potential biological link 
between C trachomatis infection and ectopic pregnancy.
Symptomatic women
Women with clinical manifestations related to C trachomatis infection, or suspected of 
having a C trachomatis infection such as those with vaginal discharge.
Symptomatic men
Men with clinical manifestations related to C trachomatis infection, or suspected of having 
a C trachomatis infection such as those with urethral discharge.
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following predictors a priori: at­risk population (panel), 
assay type (NAAT, culture, other assays detecting current 
infection, serological assays detecting anti­C trachomatis 
immunoglobulins of class IgG, IgM, IgA, immunoglobu­
lins not specified, and unclear), sampling methodology 
(non­probability­based sampling vs probability­based 
sampling), sample size (<200 vs ≥200 participants), 
response rate (≥80% vs <80% and unclear), year of 
publication, year of data collection, country (Egypt, Iran, 
Pakistan, and remaining countries; Egypt, Iran, and 
Pakistan being the most populous in the Middle East 
and north Africa),33 and sex (women vs men; men­to­
women transgenders who were biologically males were 
considered as men).
Studies that assessed C trachomatis prevalence using 
different diagnostics or biomarkers were included 
independently. Missing values for year of data collection 
were imputed using data for year of publication adjusted 
Figure 1: Flow chart of the study selection process for the systematic review
The systematic review focused on Chlamydia trachomatis incidence or prevalence, or both, in the Middle East and north Africa. *Reasons for exclusion: 14 studies 
applied the same assay to different biological specimens, and prevalence was included only once based on a sequential order prioritising for women C trachomatis 
detection in endocervical swabs followed by vaginal and urine samples, and for men detection in urethral swabs followed by urine and semen samples; one study 
applied antigen detection assays (other than nucleic acid amplification assays and culture) to the same biological specimen, and prevalence was included only once 
based on assay sensitivity; two studies were conducted only on subsamples of an original sample, and the prevalence in the original sample was included in the 
systematic review; six studies and three reports used tissue specimens from the upper genital tract; and one study had a sample size of less than 10.
1066 citations identified
 509 from PubMed
 557 from Embase
539 citations identified for title and abstract screening
465 citations identified through regional databases
 294 from WHO Index Medicus for the Eastern Mediterranean region
 48 from Iraqi Academic Scientific Journals database
 116 from Iran’s Scientific Information Database
 7 from abstract archives of international conferences
74 reports excluded
 15 did not meet eligibility criteria
 23 full-text reports did not include data for relevant outcomes
 22 full-text reports could not be retrieved and abstract does not have data 
  for relevant outcomes
 1 conference proceedings did not include data for relevant outcomes
 13 abstracts and full-text reports could not be retrieved
527 duplicates excluded
30 additional reports included
 16 identified through the Middle East and North Africa HIV/AIDS 
  Epidemiology Synthesis Project database
 14 identified through references and reviews
302 unique reports retrieved for full-text screening
 224 from PubMed and Embase
 78 from regional databases
228 eligible reports
3 reports including 8 chlamydia prevalence measures or studies and 
   16 additional prevalence measures or studies excluded*
255 reports contributing 552 chlamydia prevalence measures eligible for inclusion in
 the systematic review and meta-analysis
258 eligible reports including 576 chlamydia prevalence measures or studies identified
315 excluded after title and abstract screening 387 excluded after title and abstract screening
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Country Study design Sampling* Sample 
size
Sex Study context Population characteristics Specimen Assay type Prevalence†
Kadi et al (1990)35 Algeria Cross-sectional Convenience 69 W Gynaecology clinic Gynaecology clinic attendees Serum MIF (IgG) 17·4%
Kadi et al (1990)35 Algeria Cross-sectional Simple random 
sampling
180 W Hospital Women seeking rubella tests Serum MIF (IgG) 26·6%
Abdel Monem et al 
(2005)36
Egypt Case-control Convenience 20 W Antenatal clinic Pregnant women Endocervical Culture 15%
Aboul Atta and 
Ibrahem (1995)37
Egypt Case-control Convenience 20 M Hospital Controls in STI study Urethral DFA 5%
Badary (1996)38 Egypt Case-control Convenience 32 W Gynaecology clinic Fertile women Endocervical DFA 12·5%
Berry and El Shabrawy 
(1996)39
Egypt Case-control Convenience 30 W Family planning 
clinic
Family planning clinic 
attendees
Serum EIA (IgG) 3·3%
Diab (1993)40 Egypt Case-control Convenience 30 W Antenatal clinic Women with full-term 
delivery
Serum EIA (IgG) 0
Draz et al (2018)41 Egypt Case-control Convenience 14 W Gynaecology clinic Healthy women Endocervical DFA 0
El-Sayed et al (2002)42 Egypt Cross-sectional Convenience 108 W Family planning 
clinic
Family planning clinic 
attendees
Urine NAAT 2·8%
El-Sayed et al (2002)42 Egypt Cross-sectional Convenience 604 W Antenatal clinic Antenatal clinic attendees Urine NAAT 1·3%
Mosbah and Nabiel 
(2016)43
Egypt Case-control Convenience 90 W Hospital Pregnant women with 
pre-eclampsia
Endocervical NAAT 4·4%
Mosbah and Nabiel 
(2016)43
Egypt Case-control Convenience 90 W Hospital Normotensive pregnant 
women
Endocervical NAAT 0
Mousa (1990)44 Egypt Cross-sectional Convenience 50 W Gynaecology clinic Gynaecology clinic attendees Endocervical DFA 2%
Nada et al (2015)45 Egypt Case-control Convenience 100 W Gynaecology clinic Gynaecology clinic attendees Endocervical NAAT 2%
Sullam et al (2001)46 Egypt Cross-sectional Multistage 
cluster sampling
1344 W Community Household survey of women Endocervical ELISA 4·2%
Zaki (1989)47 Egypt Cross-sectional Convenience 100 W Antenatal clinic Pregnant women Endocervical Culture 3%
Ahmadi et al (2016a)48 Iran Case-control Convenience 109 W Family planning 
clinic
Family planning clinic 
attendees
Endocervical NAAT 11·9%
Ahmadi et al (2018)49 Iran Case-control Convenience 165 M Clinic Fertile men Semen NAAT 0·6%
Ahmadnia et al 
(2016)50
Iran Cross-sectional Stratified cluster 
sampling
4274 W Primary 
health-care centre
Primary health-care centre 
clinic attendees
Endocervical Culture 1%
Badami and Salari 
(2001)51
Iran Cross-sectional Convenience 250 W Family planning 
clinic
Family planning clinic 
attendees
Serum DFA 0·8%
Badami and Salari 
(2001)51
Iran Cross-sectional Convenience 250 W Family planning 
clinic
Family planning clinic 
attendees
Serum Unclear 3·2%
Baghchesaraei et al 
(2011)52
Iran Cross-sectional Convenience 328 W Gynaecology clinic Gynaecology clinic attendees Serum EIA (IgM) 10·3%
Bagheri et al (2018)53 Iran Case-control Convenience 60 W Fertility centre Pregnant women Vaginal NAAT 0
Bagheri et al (2018)53 Iran Case-control Convenience 60 W Fertility centre Pregnant women Serum ELISA (IgA) 6·7%
Bagheri et al (2018)53 Iran Case-control Convenience 60 W Fertility centre Pregnant women Serum ELISA (IgG) 1·7%
Behroozi (2001)54 Iran Cross-sectional Convenience 400 W Antenatal clinic Pregnant women Unclear DFA 2·8%
Chamani-Tabriz et al 
(2008)55
Iran Cross-sectional Convenience 991 W Community Married women Urine NAAT 12·8%
Cheraghi et al (2014)56 Iran Cross-sectional Convenience 1448 W Health centres Non-pregnant women Endocervical Unclear 0·2%
Dehghan et al (2017)57 Iran Case-control Convenience 250 W Antenatal clinic Antenatal clinic attendees Urine NAAT 0
Dehghan et al (2017)57 Iran Case-control Convenience 250 W Antenatal clinic Antenatal clinic attendees Serum EIA (IgA) 0
Dehghan et al (2017)57 Iran Case-control Convenience 250 W Antenatal clinic Antenatal clinic attendees Serum EIA (IgM) 0
Dehghan et al (2017)57 Iran Case-control Convenience 250 W Antenatal clinic Antenatal clinic attendees Serum EIA (IgG) 12·8%
Goshayeshi et al 
(2015)58
Iran Case-control Convenience 30 W Fertility centre Fertile women Endocervical NAAT 3·3%
Haghighi Hasanabad 
et al (2013)59
Iran Cross-sectional Convenience 399 W Antenatal clinic Pregnant adolescents Unclear NAAT 12·3%
Jahromi et al (2010)60 Iran Case-control Convenience 200 W Gynaecology clinic Women with full-term 
delivery
Endocervical DFA 5·2%
Javanmard et al 
(2018)61
Iran Cross-sectional Convenience 210 W Gynaecology clinic Women undergoing routine 
pap smear
Endocervical NAAT 11·4%
(Table 1 continues on next page)
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size
Sex Study context Population characteristics Specimen Assay type Prevalence†
(Continued from previous page)
Joolayi et al (2017)62 Iran Case-control Convenience 125 W Hospital Pregnant women Vaginal NAAT 1·6%
Joolayi et al (2017)62 Iran Case-control Convenience 125 W Hospital Pregnant women Serum ELISA (IgM) 1·6%
Joolayi et al (2017)62 Iran Case-control Convenience 125 W Hospital Pregnant women Serum ELISA (IgG) 0
Kajbaf and 
Gholamnezhad 
(1998)63
Iran Case-control Convenience 50 W Antenatal clinic Antenatal clinic attendees Endocervical DFA 4%
Kajbaf and 
Gholamnezhad 
(1998)63
Iran Case-control Convenience 50 W Antenatal clinic Antenatal clinic attendees Serum ELISA (IgG) 6%
Kamyabi (2009)64 Iran Case-control Convenience 35 W Gynaecology clinic Pregnant women Serum ELISA (IgG) 20%
Khezerdoust et al 
(2009)65
Iran Cross-sectional Convenience 1114 W Antenatal clinic Pregnant women Serum ELISA (IgG) 2·9%
Marashi et al (2014)66 Iran Case-control Convenience 200 W Antenatal clinic Pregnant women Endocervical DFA 3·5%
Marashi et al (2014)66 Iran Case-control Convenience 200 W Antenatal clinic Pregnant women Endocervical NAAT 8·7%
Ministry of Health 
and Medical 
Education (2008)67
Iran Case-control Convenience 41 W Clinic Fertile women Serum ELISA (IgG) 2·4%
Meidani (2009)68 Iran Cross-sectional Simple random 
sampling
140 M Laboratory Men—premarital or pre-
employment screening
Urine NAAT 0·7%
Ministry of Health 
and Medical 
Education (2008)67
Iran Cross-sectional Convenience 70 W Antenatal clinic Pregnant women Serum ELISA 
(unclear)
4·3%
Ministry of Health 
and Medical 
Education (2008)67
Iran Case-control Convenience 250 W Family planning 
clinic
Healthy women Endocervical DFA 0·8%
Mousavi et al (2014)69 Iran Case-control Convenience 104 W Antenatal clinic Antenatal clinic attendees Endocervical NAAT 5·8%
Pourabbas et al 
(2018)70
Iran Cross-sectional Convenience 239 W Hospital Pregnant women Endocervical NAAT 15·5%
Rashidi et al (2013)71 Iran Case-control Convenience 223 W Antenatal clinic Pregnant women Serum ELISA (IgM) 1·8%
Rashidi et al (2013)71 Iran Case-control Convenience 223 W Antenatal clinic Pregnant women Serum ELISA (IgG) 5·0%
Rashidi et al (2013)71 Iran Case-control Convenience 223 W Antenatal clinic Pregnant women Urine NAAT 8·5%
Rohi et al (2011)72 Iran Cross-sectional Convenience 91 W Hospital Pregnant women Serum ELISA (IgG) 28·6%
Rostami et al (2016)73 Iran Cross-sectional Simple random 
sampling
518 W Gynaecology clinic Gynaecology clinic 
attendees
Endocervical NAAT 7·1%
Safdari et al (2015)74 Iran Cross-sectional Convenience 70 W Antenatal clinic Antenatal clinic attendees Endocervical NAAT 10%
Safdari et al (2015)74 Iran Cross-sectional Convenience 70 W Antenatal clinic Antenatal clinic attendees Endocervical Culture 8·6%
Sattari et al (2017)75 Iran Case-control Convenience 100 W Antenatal clinic Pregnant women Serum ELISA (IgM) 2%
Sattari et al (2017)75 Iran Case-control Convenience 100 W Antenatal clinic Pregnant women Serum ELISA (IgG) 18%
Sisakht et al (2017)76 Iran Case-control Convenience 30 W Gynaecology clinic Women with full-term 
delivery
Urine NAAT 4·7%
Yeganeh et al (2013)77 Iran Case-control Convenience 100 M Urology clinic Asymptomatic men Urine NAAT 4%
Zahirnia et al (2018)78 Iran Cross-sectional Convenience 76 W Gynaecology clinic Pregnant women Vaginal NAAT 10·5%
Abdulkhudher et al 
(2014)79
Iraq Case-control Convenience 40 W Antenatal clinic Women with full-term 
delivery
Serum ELISA (IgM) 0
Abdulkhudher et al 
(2014)79
Iraq Case-control Convenience 40 W Antenatal clinic Women with full-term 
delivery
Serum ELISA (IgG) 7·5%
Abdul-Karim et al 
(2009)80
Iraq Cross-sectional Convenience 198 W Hospital Women with full-term 
delivery
Serum ELISA (IgG) 13·7%
Abdullah (2012)81 Iraq Case-control Convenience 24 W Hospital Pregnant women Serum ELISA (IgM) 0
Abdullah (2012)81 Iraq Case-control Convenience 24 W Hospital Pregnant women Serum ELISA (IgG) 8·3%
Ahmed (2008)82 Iraq Case-control Convenience 30 W Hospital Women with full-term 
delivery
Serum ELISA 
(unclear)
0
Al-Hamdani et al 
(2010)83
Iraq Case-control Convenience 17 W Hospital Pregnant women Serum ELISA (IgM) 14·0%
(Table 1 continues on next page)
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(Continued from previous page)
Al-Hamdani et al 
(2010)83
Iraq Case-control Convenience 17 W Hospital Pregnant women Serum ELISA (IgG) 14·0%
Al-Hamdani et al 
(2010)83
Iraq Case-control Convenience 17 W Hospital Pregnant women Serum ELISA (IgA) 40·4%
Al-Husseinei et al 
(2009)84
Iraq Case-control Convenience 100 W Family planning 
clinic
Family planning clinic 
attendees
Serum IFAT 
(unclear)
5%
Al-Husseinei et al 
(2009)84
Iraq Case-control Convenience 100 W Family planning 
clinic
Family planning clinic 
attendees
Endocervical ELFA 4%
Ali and Al-Kazaz 
(2018)85
Iraq Case-control Convenience 13 M Clinic Fertile men Semen NAAT 0
Alkhafaf (2013)86 Iraq Case-control Convenience 122 W Hospital Married women Serum ELISA (IgG) 4·1%
Alkhafaf (2013)86 Iraq Case-control Convenience 168 W Hospital Unmarried woman Serum ELISA (IgG) 2·4%
Hwaid et al (2013)87 Iraq Case-control Simple random 
sampling
91 W Antenatal clinic Pregnant women Serum ELISA (IgG) 5·5%
Hwaid et al (2013)87 Iraq Case-control Simple random 
sampling
91 W Antenatal clinic Pregnant women Serum ELISA (IgM) 3·3%
Ismail and Ali (2012)88 Iraq Case-control Convenience 50 W Laboratories General population women Serum ELISA (IgM) 10%
Ismail and Ali (2012)88 Iraq Case-control Convenience 50 W Laboratories General population women Serum ELISA (IgG) 4%
Ismail and Ali (2012)88 Iraq Case-control Convenience 50 W Laboratories General population women Serum ELISA (IgA) 2%
Mohammed et al 
(2012)89
Iraq Case-control Convenience 23 W Gynaecology clinic Pregnant women Serum ELISA (IgM) 0
Mohammed et al 
(2017)90
Iraq Case-control Convenience 20 W Gynaecology clinic Gynaecology clinic attendees Endocervical NAAT 0
Mohammed et al 
(2017)90
Iraq Case-control Convenience 20 W Gynaecology clinic Gynaecology clinic attendees Serum ELISA (IgG) 0
Yahya and Al-Siraj 
(2009)91
Iraq Cross-sectional Convenience 296 M Laboratory Fertile men Serum Culture 0
Abusarah et al (2013)92 Jordan Case-control Convenience 61 M Urology clinics Fertile men Urine NAAT 1·6%
Al-Ramahi et al 
(2008)93
Jordan Case-control Convenience 146 W Gynaecology clinic Gynaecology clinic attendees Endocervical NAAT 0·7%
As’ad (2004)94 Jordan Cross-sectional Convenience 144 W Family planning 
clinic
Asymptomatic women Vaginal NAAT 0
Awwad et al (2003)95 Jordan Case-control Convenience 61 M Urology clinic Non-urethritis patients Urine NAAT 0
Awwad et al (2003)95 Jordan Case-control Convenience 39 W Urology clinic Non-urethritis patients Urine NAAT 0
Mahafzah et al 
(2008)96
Jordan Cross-sectional Convenience 186 W Gynaecology clinic Family planning clinic 
attendees
Endocervical NAAT 0·5%
Jordan Ministry of 
Health (2004)97
Jordan Cross-sectional Convenience 213 W Hospital Asymptomatic women Endocervical NAAT 0·5%
Al-Awadhi et al 
(2018)98
Kuwait Cross-sectional Convenience 65 338 W Laboratory Women undergoing pap 
smear 1997–2005
Endocervical Unclear 0·1%
Al-Awadhi et al 
(2018)98
Kuwait Cross-sectional Convenience 56 105 W Laboratory Women undergoing pap 
smear 2006–14
Endocervical Unclear 0·04%
Al-Sweih et al (2011)99 Kuwait Cross-sectional Convenience 5938 W Primary 
health-care centre
Kuwaiti women Vaginal NAAT 1·9%
Al-Sweih et al (2011)99 Kuwait Cross-sectional Convenience 2601 W Primary 
health-care centre
Expatriate women Vaginal NAAT 2·3%
Al-Sweih et al 
(2012)100
Kuwait Case-control Convenience 188 M Gynaecology clinic Fertile men Semen NAAT 3·7%
Deeb et al (2003)101 Lebanon Cross-sectional Multistage 
random 
sampling
506 W Community Ever-married women Endocervical ELISA 0
Hancali et al (2015)102 Morocco Cross-sectional Convenience 760 W Family planning 
clinic
Family planning clinic 
attendees in 1999
Unclear NAAT 4·0%
Hancali et al (2015)102 Morocco Cross-sectional Convenience 256 W Family planning 
clinic
Family planning clinic 
attendees in 2011
Unclear NAAT 4·4%
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Hulstein et al (2018)103 Morocco Cross-sectional Simple random 
sampling
163 M Community General population men Serum IFAT (IgG) 31·3%
Hulstein et al (2018)103 Morocco Cross-sectional Simple random 
sampling
174 W Community General population women Serum IFAT (IgG) 37·9%
Morocco Ministry of 
Health (2001)104
Morocco Cross-sectional Convenience 323 W Antenatal clinic Pregnant women Urine NAAT 2·7%
Morocco Ministry of 
Health (2001)104
Morocco Cross-sectional Convenience 518 W Family planning 
clinic
Family planning clinic 
attendees
Urine NAAT 5·2%
The Middle East and 
North Africa HIV/AIDS 
Epidemiology 
Synthesis Project 
(2017)105
Morocco Cross-sectional Convenience 252 W Antenatal clinic Pregnant women Unclear NAAT 3·6%
The Middle East and 
North Africa HIV/AIDS 
Epidemiology 
Synthesis Project 
(2017)105
Morocco Cross-sectional Convenience 537 W Family planning 
clinic
Family planning clinic 
attendees
Unclear NAAT 3%
Radouani et al 
(1998)106
Morocco Case-control Convenience 81 W Hospital Pregnant women Serum MIF 
(unclear)
14·8%
Radouani et al 
(1998)106
Morocco Case-control Convenience 200 M Hospital Blood donors Serum MIF 
(unclear)
4·5%
Takourt et al (1995)107 Morocco Case-control Convenience 200 M Hospital Blood donors Serum MIF 
(unclear)
5·0%
Takourt et al (1995)107 Morocco Case-control Convenience 200 W Hospital Blood donors Serum MIF 
(unclear)
10·0%
Mir et al (2009)108 Pakistan Cross-sectional Multistage 
systematic 
random 
sampling
2383 M Community General population men Urine NAAT 0
Wasti et al (1997)109 Pakistan Cross-sectional Convenience 300 W Antenatal clinic 
and family 
planning clinic
Antenatal clinic and family 
planning clinic attendees
Endocervical DFA 5·3%
Al-Thani et al (2013)110 Qatar Cross-sectional Convenience 133 W Primary 
health-care centre
Qatari women Endocervical NAAT 5·3%
Al-Thani et al (2013)110 Qatar Cross-sectional Convenience 218 W Primary 
health-care centre
Non-Qatari women Endocervical NAAT 5·5%
Alzahrani et al 
(2010)111
Saudi Arabia Cross-sectional Simple random 
sampling
95 W Antenatal clinic Pregnant women Endocervical ELISA 10·5%
Awad et al (2013)112 Saudi Arabia Cross-sectional Convenience 144 W Gynaecology clinic Antenatal clinic attendees Urine NAAT 11·1%
Bashi (1987)113 Saudi Arabia Cross-sectional Convenience 100 W Primary 
health-care centre
Primary health-care centre 
attendees
Serum MIF (IgG) 0
Bashi (1987)113 Saudi Arabia Cross-sectional Convenience 100 M Primary 
health-care centre
Primary health-care centre 
attendees
Serum MIF (IgG) 2%
Ghazi et al (2006)114 Saudi Arabia Cross-sectional Simple random 
sampling
1600 W Antenatal clinic Saudi pregnant women Serum ELISA (IgG) 8·7%
Ghazi et al (2006)114 Saudi Arabia Cross-sectional Simple random 
sampling
1460 W Antenatal clinic Saudi pregnant women Serum ELISA (IgM) 1·5%
Hossain (1988)115 Saudi Arabia Cross-sectional Convenience 112 M Hospital Blood donors Serum MIF (IgM) 0
Hossain (1988)115 Saudi Arabia Cross-sectional Convenience 112 M Hospital Blood donors Serum MIF (IgG) 1·8%
Kamel (2013)116 Saudi Arabia Randomised 
controlled trial‡
Convenience 100 W Antenatal clinic Antenatal clinic attendees Serum ELISA (IgG) 4·0%
Massoud et al (1991)117 Saudi Arabia Case-control Convenience 100 W Hospital Asymptomatic women Serum IFAT 
(unclear)
0
Massoud et al (1991)117 Saudi Arabia Case-control Convenience 100 M Hospital Asymptomatic men Serum IFAT 
(unclear)
2·0%
Ismail et al (1990)118 Somalia Cross-sectional Convenience 194 W Community Women Endocervical EIA 12·4%
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by the median difference between year of publication 
and year of data collection (for studies with complete 
information). We did meta­regression diagnostics.
Factors associated with prevalence at p≤0·20 in 
univariable analysis were eligible for inclusion in the 
multi variable analysis. In the multivariable model, a 
p≤0·05 for any given factor indicated strong evidence for 
an association with C trachomatis prevalence. We did 
meta­regression models using Stata/SE (version 14).34
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the article. The corresponding author had full access to 
all the data in the study and had the final responsibility 
for the decision to submit for publication.
Results
The search identified a total of 1531 citations: 509 through 
PubMed, 557 through Embase, and 465 through regional 
and national databases. Of these citations, 302 reports 
underwent full­text screening after excluding duplicates 
and screening titles and abstracts. During full­text screen­
ing, 228 eligible reports were identified, and 74 were 
excluded for reasons outlined in figure 1. Hand­searching 
of reference lists of relevant reports and reviews yielded 
14 additional eligible reports. 16 country­level reports 
were further identified through the Middle East and 
North Africa HIV/AIDS Epidemiology Synthesis Project 
database. Three reports were subsequently excluded. In 
total, 255 reports contributing 552 prevalence measures 
or studies met the eligibility criteria for inclusion, but no 
incidence measures were identified.
Evidence covered 20 (87%) of 23 countries, encom­
passing a total of 256 769 C trachomatis test results 
(tables 1 and 2; appendix pp 9–14). Iran contributed the 
largest number of measures or studies (n=176), followed 
by Egypt (n=89), Iraq (n=72), Saudi Arabia (n=45), 
Pakistan (n=42), and Morocco (n=32). Most studies 
assessed cur rent infection (n=318), whereas the rest 
reported different serological measures (n=211), such as 
ever infection (anti­C trachomatis IgG; n=117). Details of 
C trachomatis testing protocol were specified in 424 (77%) 
of 552 studies; 320 (75%) of the 424 used commercial 
assays, 62 (15%) used in­house validated tests, 29 (7%) 
used culture, and 13 (3%) used a non­validated in­house 
test.
In general populations (n=137), prevalence of current 
genital infection ranged from 0 to 19·9% with a median 
of 3·0%, whereas ever infection prevalence ranged from 
0 to 37·9% with a median of 4·7% (tables 1 and 3).
In populations at high risk (n=40), current infection 
prevalence in female sex workers (n=20) ranged from 
0·9% to 72·9% with a median of 8·4%, whereas ever 
infection prevalence ranged from 19·8% to 100% with a 
median of 90·0% (tables 2 and 3). In men who have sex 
with men (including male sex workers and male­to­
female transgenders; n=20), current infection prevalence 
ranged from 0 to 8·8% with a median of 1·2% for genital 
infections and from 3·6% to 18·3% with a median of 
6·3% for rectal infections, but no ever infection measure 
was identified.
Country Study design Sampling* Sample 
size
Sex Study context Population characteristics Specimen Assay type Prevalence†
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Ismail et al (1990)118 Somalia Cross-sectional Convenience 189 M Community Men Urethral EIA 6%
Nur et al (2000)119 Somalia Cross-sectional Convenience 54 M Hospital Blood donors Serum EIA (IgG) 22·2%
WHO (2005a)120 Somalia Cross-sectional Convenience 4723 W Antenatal clinic Pregnant women Urine NAAT 1·7%
WHO (2005b)121 Somalia Cross-sectional Convenience 509 W Antenatal clinic Pregnant women Urine NAAT 1·4%
Ahmed et al (2018)122 Sudan Case-control Convenience 93 W Hospital Healthy pregnant women Serum ELISA (IgG) 0
Ahmed et al (2018)122 Sudan Case-control Convenience 93 W Hospital Pregnant women with 
pre-eclampsia
Serum ELISA (IgG) 0
Almroth et al 
(2005)123
Sudan Case-control Convenience 139 W Antenatal clinic Antenatal clinic attendees Serum EIA (IgG) 3·6%
Ortashi et al (2004)124 Sudan Cross-sectional Convenience 151 W Antenatal clinic Pregnant women Endocervical 
and urethral
EIA 19·9%
Alkayer et al (2017)125 Syria Case-control Convenience 21 W Hospital Pregnant women Serum ELISA (IgG) 4·7%
Ghazal-Aswad et al 
(2006)126
United Arab 
Emirates
Cross-sectional Multistage 
cluster sampling
727 W Clinics Primary health-care centre 
and clinic attendees
Endocervical EIA 2·5%
DFA=direct fluorescent assay. EIA=enzyme immunoassay. ELFA=enzyme-linked fluorescence assay. IFAT=indirect fluorescent antibody test. M=men or sample predominantly of men. 
MIF=micro-immunofluorescence. NAAT=nucleic acid amplification test. STI=sexually transmitted infection. W=women or sample predominantly of women. *Non-probability sampling refers to a sampling 
method in which the data collection process does not allow individuals to have equal chance of being selected; an example is convenience sampling for which individuals are selected on the basis of ease of 
accessibility (first-come first-served basis).127,128 Probability-based sampling refers to a sampling method in which data collection process is based on a random selection of study participants; an example is 
random sampling from a sampling frame.128 Another example of probability-based sampling is respondent-driven sampling, which is a sampling method specifically designed to sample hard-to-reach 
populations and is based on chain referral with the probability of selection calculated at each step in the network to produce adjusted prevalence estimates.129 †The decimal places of the prevalence measures are 
as reported in the original report, but prevalence figures with more than one decimal place were rounded to one decimal place. ‡The extracted prevalence measure is for the baseline measurement.
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Populations at high risk
Kadi et al (1990)35 Algeria Cross-sectional Convenience 44 W Community Female sex workers Serum MIF (IgG) 100%
El-Sayed et al (2002)42 Egypt Cross-sectional Convenience 52 W Community Female sex workers Urine NAAT 7·7%
El-Sayed et al (2002)42 Egypt Cross-sectional Convenience 80 M Community Men who have sex with men Urine NAAT 8·8%
Darougar et al (1983)130 Iran Cross-sectional Convenience 116 W Community Female sex workers Endocervical Culture 6·9%
Darougar et al (1983)130 Iran Cross-sectional Convenience 154 W Community Female sex workers Serum MIF (IgM) 29·2%
Darougar et al (1983)130 Iran Cross-sectional Convenience 154 W Community Female sex workers Serum MIF (IgG) 94·2%
Kassaian et al (2012)131 Iran Cross-sectional Convenience 91 W Mixed Female sex workers Serum ELISA (IgG) 19·8%
Kazerooni et al (2014)132 Iran Cross-sectional Respondent-driven 
sampling
278 W Community Female sex workers Vaginal NAAT 9%
Mirzazadeh et al (2016)133 Iran Cross-sectional Convenience 1337 W Community Female sex workers Vaginal NAAT 6%
Al-Husseinei et al (2009)84 Iraq Case-control Convenience 30 W STI clinic Women with multiple partners Endocervical ELFA 30%
Al-Husseinei et al (2009)84 Iraq Case-control Convenience 30 W STI clinic Women with multiple partners Serum IFAT 
(unclear)
36·7%
Bellaji et al (2017)134 Morocco Cross-sectional Convenience 519 W NGOs Female sex workers Endocervical 
and vaginal
NAAT 20·7%
Morocco Ministry of 
Health (2008)135
Morocco Cross-sectional Convenience 141 W STI clinic Female sex workers Endocervical 
and urine
NAAT 22·7%
Morocco Ministry of 
Health (2011)136
Morocco Cross-sectional Respondent-driven 
sampling
368 W Community Female sex workers in Agadir Endocervical NAAT 22·4%
Morocco Ministry of 
Health (2015)137
Morocco Cross-sectional Respondent-driven 
sampling
247 M Community Men who have sex with men 
in Agadir
Urine NAAT 5·4%
Morocco Ministry of 
Health (2015)137
Morocco Cross-sectional Respondent-driven 
sampling
252 M Community Men who have sex with men 
in Marrakech
Urine NAAT 6·5%
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
426 W Community Female sex workers in 
Rawalpindi
Endocervical NAAT 1·7%
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
107 W Community Female sex workers in 
Abbottabad
Endocervical NAAT 0·9%
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
195 M Community Male sex workers in 
Rawalpindi (Bantha)
Urine NAAT 0
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
195 M Community Male sex workers in 
Rawalpindi (Bantha)
Rectal NAAT 4·7%
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
364 M Community Male sex workers in 
Rawalpindi (Khotki)
Urine NAAT 0
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
364 M Community Male sex workers in 
Rawalpindi (Khotki)
Rectal NAAT 3·6%
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
253 M Community Male sex workers in 
Rawalpindi (Khusra)
Urine NAAT 0
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
253 M Community Male sex workers in 
Rawalpindi (Khusra)
Rectal NAAT 9·9%
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
83 M Community Male sex workers in 
Abbottabad (Bantha)
Urine NAAT 1·2%
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
83 M Community Male sex workers in 
Abbottabad (Bantha)
Rectal NAAT 4·9%
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
20 M Community Male sex workers in 
Abbottabad (Khotki and 
Khusra)
Urine NAAT 0
Hawkes et al (2009)138 Pakistan Cross-sectional Respondent-driven 
sampling
20 M Community Male sex workers in 
Abbottabad (Khotki and 
Khusra)
Rectal NAAT 6·3%
Khan et al (2011)139 Pakistan Cross-sectional Respondent-driven 
sampling
730 W Community Female sex workers in Lahore Endocervical NAAT 7·7%
Osama (2017)140 Pakistan Cross-sectional Convenience 2531 M Drop in 
centre
Men who have sex with men 
in Lahore
Unclear Unclear 35·2%
Rehan et al (2009)141 Pakistan Cross-sectional Systematic random 
sampling
383 W Red-light Female sex workers in Lahore Endocervical NAAT 11%
Rehan et al (2009)141 Pakistan Cross-sectional Snowball 348 W Community Female sex workers in Karachi Endocervical NAAT 5·2%
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Rehan et al (2009)141 Pakistan Cross-sectional Respondent-driven 
sampling
395 M Community Male sex workers in Lahore Urethral NAAT 1·5%
Rehan et al (2009)141 Pakistan Cross-sectional Snowball 396 M Community Male sex workers in Karachi Urethral NAAT 1·2%
Rehan et al (2009)141 Pakistan Cross-sectional Snowball 394 M Community Male sex workers in Karachi Rectal NAAT 10·4%
Rehan et al (2009)141 Pakistan Cross-sectional Systematic random 
cluster sampling
198 M Community Hijras in Lahore Urethral NAAT 1·5%
Rehan et al (2009)141 Pakistan Cross-sectional Systematic random 
cluster sampling
197 M Community Hijras in Karachi Urethral NAAT 0
Rehan et al (2009)141 Pakistan Cross-sectional Systematic random 
cluster sampling
197 M Community Hijras in Karachi Rectal NAAT 18·3%
Znazen et al (2010)142 Tunisia Cross-sectional Convenience 188 W Community Female sex workers Endocervical NAAT 72·9%
Znazen et al (2010)142 Tunisia Cross-sectional Convenience 183 W Community Female sex workers Serum MIF (IgG) 85·8%
Infertility clinic attendees
Abdel Aleem et al 
(1996)143
Egypt Case-control Convenience 144 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Serum ELISA (IgG) 52%
Abdel Aleem et al 
(1996)143
Egypt Case-control Convenience 104 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Serum ELISA (IgG) 24%
Abdel Monem et al 
(2005)36
Egypt Case-control Convenience 150 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Endocervical Culture 24%
Abdel Monem et al 
(2005)36
Egypt Case-control Convenience 150 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Endocervical EIA 22·7%
Abdella et al (2015)144 Egypt Case-control Convenience 50 W Infertility 
clinic
Women with idiopathic 
infertility
Serum ELISA (IgM) 4%
Abdella et al (2015)144 Egypt Case-control Convenience 50 W Infertility 
clinic
Women with idiopathic 
infertility
Serum ELISA (IgG) 36%
Abdella et al (2015)144 Egypt Case-control Convenience 50 W Infertility 
clinic
Women with idiopathic 
infertility
Endocervical NAAT 6%
Azab and Hassouna 
(2008)145
Egypt Cross-sectional Convenience 70 W Infertility 
clinic
Nearly half of women with TFI Serum ELISA (IgG) 28·6%
Badary (1996)38 Egypt Case-control Convenience 60 W Infertility 
clinic
Women with idiopathic 
infertility
Endocervical DFA 33%
Berry and El Shabrawy 
(1996)39
Egypt Case-control Convenience 70 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Serum EIA (IgG) 18·6%
Elkayal et al (2015)146 Egypt Case-control Convenience 100 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Endocervical ELISA 3%
Elkayal et al (2015)146 Egypt Case-control Convenience 100 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Endocervical NAAT 3%
El Sayed et al (1997)147 Egypt Cross-sectional Convenience 22 W Infertility 
clinic
Women with TFI Serum MIF (IgG) 81·8%
El Sayed et al (1997)147 Egypt Cross-sectional Convenience 78 W Infertility 
clinic
Women without TFI Serum MIF (IgG) 7·7%
Inhorn and Buss (1993)148 Egypt Case-control Convenience 83 W Hospital Majority of women without 
TFI
Unclear Unclear 33%
Makled et al (2013)149 Egypt Cross-sectional Simple random 
sampling
27 W Infertility 
clinic
Women with TFI Serum ELISA (IgG) 85·2%
Makled et al (2013)149 Egypt Cross-sectional Simple random 
sampling
51 W Infertility 
clinic
Women without TFI Serum ELISA (IgG) 13·7%
Nada et al (2015)45 Egypt Case-control Convenience 100 W Infertility 
clinic
Women with idiopathic 
infertility
Endocervical NAAT 15%
Sadek et al (1993)150 Egypt Case-control Convenience 43 W Infertility 
clinic
Infertile women in infertile 
couples with sperm antibodies
Unclear DFA 18·6%
Sadek et al (1993)150 Egypt Case-control Convenience 37 W Infertility 
clinic
Women partners in infertile 
couples with sperm antibodies
Unclear DFA 18·9%
Sadek et al (1993)150 Egypt Case-control Convenience 62 M Infertility 
clinic
Men partners in infertile 
couples with sperm antibodies
Unclear DFA 19·4%
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Sadek et al (1993)150 Egypt Case-control Convenience 18 M Infertility 
clinic
Infertile men in infertile 
couples with sperm antibodies
Unclear DFA 22·2%
Siam and Hefzy (2012)151 Egypt Case-control Convenience 90 W Gynaecology 
clinic
Women with idiopathic 
infertility
Serum ELISA (IgG) 20%
Siam and Hefzy (2012)151 Egypt Case-control Convenience 90 W Gynaecology 
clinic
Women with idiopathic 
infertility
Urine NAAT 4·4%
Younis et al (2000)152 Egypt Cross-sectional Convenience 30 W Infertility 
clinic
Women with TFI Serum MIF (IgG) 46·7%
Younis et al (2000)152 Egypt Cross-sectional Convenience 14 W Infertility 
clinic
Women without TFI Serum MIF (IgG) 50·0%
Zaitun and Zaitoun 
(1990)153
Egypt Cross-sectional Convenience 20 W Infertility 
clinic
Women with TFI Serum Unclear 25%
Zaitun and Zaitoun 
(1990)153
Egypt Cross-sectional Convenience 30 W Infertility 
clinic
Women without TFI Serum Unclear 3·3%
Zaki (1989)47 Egypt Cross-sectional Convenience 100 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Endocervical Culture 7%
Zytoon (1994)154 Egypt Cross-sectional Convenience 75 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Endocervical Culture 65·3%
Ahmadi et al (2018)49 Iran Case-control Convenience 165 M Infertility 
clinic
Men with male factor 
infertility
Semen NAAT 4·2%
Badami and Salari (2001)51 Iran Case-control Convenience 125 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Serum DFA 8·8%
Badami and Salari (2001)51 Iran Case-control Convenience 125 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Serum Unclear 20·8%
Dehghan et al (2017)57 Iran Case-control Convenience 250 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Urine NAAT 4·8%
Dehghan et al (2017)57 Iran Case-control Convenience 250 M Infertility 
clinic
40% of men had male factor 
infertility
Urine NAAT 4·4%
Dehghan et al (2017)57 Iran Case-control Convenience 250 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Serum EIA (IgM) 4%
Dehghan et al (2017)57 Iran Case-control Convenience 250 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Serum ELISA (IgA) 0
Dehghan et al (2017)57 Iran Case-control Convenience 250 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Serum ELISA (IgG) 15·6%
Dehghan et al (2017)57 Iran Case-control Convenience 250 M Infertility 
clinic
40% of men had male factor 
infertility
Serum EIA (IgM) 1·2%
Dehghan et al (2017)57 Iran Case-control Convenience 250 M Infertility 
clinic
40% of men had male factor 
infertility
Serum ELISA (IgA) 0
Dehghan et al (2017)57 Iran Case-control Convenience 250 M Infertility 
clinic
40% of men had male factor 
infertility
Serum ELISA (IgG) 18%
Golshani et al (2007)155 Iran Cross-sectional Convenience 200 M Infertility 
clinic
Majority of men had male 
factor infertility
Semen NAAT 18·0%
Goshayeshi et al (2015)58 Iran Case-control Convenience 100 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Endocervical NAAT 21·0%
Hajikhani et al (2013)156 Iran Cross-sectional Convenience 51 W Infertility 
clinic
Women with TFI Endocervical Culture 3·9%
Hajikhani et al (2013)156 Iran Cross-sectional Convenience 51 W Infertility 
clinic
Women with TFI Endocervical NAAT 11·7%
Joolayi et al (2017)62 Iran Case-control Convenience 32 W Infertility 
clinic
Women with TFI Vaginal NAAT 9·4%
Joolayi et al (2017)62 Iran Case-control Convenience 68 W Infertility 
clinic
Women with ovarian and 
other infertility
Vaginal NAAT 2·9%
Joolayi et al (2017)62 Iran Case-control Convenience 32 W Infertility 
clinic
Women with TFI Serum ELISA (IgM) 9·4%
Joolayi et al (2017)62 Iran Case-control Convenience 68 W Infertility 
clinic
Women with ovarian and 
other infertility
Serum ELISA (IgM) 4·4%
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Joolayi et al (2017)62 Iran Case-control Convenience 32 W Infertility 
clinic
Women with TFI Serum ELISA (IgG) 0
Joolayi et al (2017)62 Iran Case-control Convenience 68 W Infertility 
clinic
Women with ovarian and 
other infertility
Serum ELISA (IgG) 0
Kajbaf and Gholamnezhad 
(1998)63
Iran Case-control Convenience 101 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Endocervical DFA 7·9%
Kajbaf and Gholamnezhad 
(1998)63
Iran Case-control Convenience 101 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Serum ELISA (IgG) 17·8%
Kalantar et al (2007)157 Iran Cross-sectional Convenience 91 W Infertility 
clinic
Majority of women had female 
factor infertility
Serum ELISA (IgG) 0
Kalantar et al (2007)157 Iran Cross-sectional Convenience 91 W Infertility 
clinic
Majority of women had female 
factor infertility
Vaginal NAAT 0
Kamyabi (2009)64 Iran Case-control Convenience 35 W Gynaecology 
clinic
Women with mixed infertility 
diagnosis
Serum ELISA (IgG) 22·9%
Mansour Ghanaie 
(2014)158
Iran Cross-sectional Convenience 135 W Infertility 
clinic
Majority of women without 
TFI
Endocervical NAAT 19·3%
Ministry of Health and 
Medical Education 
(2008)67
Iran Case-control Convenience 46 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Serum ELISA (IgG) 23·9%
Marashi et al (2014)66 Iran Case-control Convenience 150 W Infertility 
clinic
Women with idiopathic 
infertility
Endocervical DFA 15·3%
Marashi et al (2014)66 Iran Case-control Convenience 150 W Infertility 
clinic
Women with idiopathic 
infertility
Endocervical NAAT 32%
Ministry of Health and 
Medical Education 
(2008)67
Iran Case-control Convenience 125 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Endocervical DFA 8·8%
Ministry of Health and 
Medical Education 
(2008)67
Iran Cross-sectional Convenience 100 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Unclear NAAT 9%
Moazenchi et al (2018)159 Iran Cross-sectional Convenience 1080 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Serum ELISA (IgA) 4·3%
Moazenchi et al (2018)159 Iran Cross-sectional Convenience 1080 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Semen NAAT 10%
Mousavi et al (2014)69 Iran Case-control Convenience 104 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Endocervical NAAT 4·8%
Nan Bakhsh et al (2008)160 Iran Cross-sectional Convenience 144 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Serum ELISA (IgG) 11·1%
Nikbakht et al (2008)161 Iran Case-control Convenience 125 W Infertility 
clinic
Women with TFI Unclear ELISA 
(unclear)
23·2%
Peivandi et al (2009)162 Iran Cross-sectional Convenience 110 W Infertility 
clinic
Majority of women with TFI Serum MIF (IgG) 24·5%
Rashidi et al (2007)163 Iran Cross-sectional Convenience 300 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Unclear ELISA 
(unclear)
32·3%
Rashidi et al (2013)71 Iran Case-control Convenience 44 W Infertility 
clinic
Women with TFI Urine NAAT 4·5%
Rashidi et al (2013)71 Iran Case-control Convenience 190 W Infertility 
clinic
Women with ovarian and 
other infertility
Urine NAAT 14·2%
Rashidi et al (2013)71 Iran Case-control Convenience 44 W Infertility 
clinic
Women with TFI Serum ELISA (IgM) 2·3%
Rashidi et al (2013)71 Iran Case-control Convenience 190 W Infertility 
clinic
Women with ovarian and 
other infertility
Serum ELISA (IgM) 0·5%
Rashidi et al (2013)71 Iran Case-control Convenience 44 W Infertility 
clinic
Women with TFI Serum ELISA (IgG) 9·1%
Rashidi et al (2013)71 Iran Case-control Convenience 190 W Infertility 
clinic
Women with ovarian and 
other infertility
Serum ELISA (IgG) 8·4%
Sadrpour et al (2013)164 Iran Cross-sectional Convenience 120 M Infertility 
clinic
Men with male factor 
infertility
Semen NAAT 3%
(Table 2 continues on next page)
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Sattari et al (2017)75 Iran Case-control Convenience 184 W Infertility 
clinic
Majority of women without 
TFI
Serum ELISA (IgM) 5·4%
Sattari et al (2017)75 Iran Case-control Convenience 184 W Infertility 
clinic
Majority of women without 
TFI
Serum ELISA (IgG) 35·9%
Siahkali and Amini 
(2018)165
Iran Cross-sectional Convenience 60 M Infertility 
clinic
Men with idiopathic infertility Semen NAAT 5·0%
Abid and Al-Zwaid 
(2015)166
Iraq Case-control Convenience 61 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Serum ELISA (IgG) 30%
Ahmed (2012)167 Iraq Case-control Convenience 47 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Endocervical NAAT 29·8%
Al-Husseinei et al (2009)84 Iraq Case-control Convenience 54 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Endocervical ELFA 9·3%
Al-Husseinei et al (2009)84 Iraq Case-control Convenience 54 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Serum IFAT 
(unclear)
11·1%
Ali and Al-Kazaz (2018)85 Iraq Case-control Convenience 63 M Clinic Men with male factor 
infertility
Semen NAAT 17·4%
Al-Kattan and 
Mohammed (2013)168
Iraq Cross-sectional Convenience 54 W Infertility 
clinic
Women with TFI or adhesions Serum ELISA (IgG) 51·9%
Al-Kattan and 
Mohammed (2013)168
Iraq Cross-sectional Convenience 67 W Infertility 
clinic
Women without TFI or 
endometriosis
Serum ELISA (IgG) 29·9%
Dawood (2011)169 Iraq Cross-sectional Convenience 30 W Hospital Women with unclear infertility 
diagnosis
Serum ELISA (IgM) 86·6%
Dawood (2011)169 Iraq Cross-sectional Convenience 30 W Hospital Women with unclear infertility 
diagnosis
Serum ELISA (IgA) 3·3%
Dawood (2011)169 Iraq Cross-sectional Convenience 30 W Hospital Women with unclear infertility 
diagnosis
Serum ELISA (IgG) 53·3%
Dawood (2011)169 Iraq Cross-sectional Convenience 100 W Hospital Women with unclear infertility 
diagnosis
Endocervical NAAT 30%
Ismail and Ali (2012)88 Iraq Case-control Convenience 52 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Serum ELISA (IgG) 25%
Ismail and Ali (2012)88 Iraq Case-control Convenience 52 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Serum ELISA (IgM) 42·3%
Ismail and Ali (2012)88 Iraq Case-control Convenience 52 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Serum ELISA (IgA) 3·8%
Mohammed et al (2017)90 Iraq Case-control Convenience 80 W Gynaecology 
clinic
Women with mixed infertility 
diagnosis
Endocervical NAAT 13·8%
Mohammed et al (2017)90 Iraq Case-control Convenience 80 W Gynaecology 
clinic
Women with mixed infertility 
diagnosis
Serum ELISA (IgG) 2·5%
Yahya and Al-Siraj 
(2009)91
Iraq Cross-sectional Convenience 296 M Laboratory Men with unclear infertility 
diagnosis
Serum Culture 4·0%
Abusarah et al (2013)92 Jordan Case-control Convenience 81 M Gynaecology 
clinic
Men with male factor 
infertility
Urine NAAT 4·9%
Al-Ramahi et al (2008)93 Jordan Case-control Convenience 66 W Infertility 
clinic
Women with idiopathic 
infertility
Endocervical NAAT 3·0%
Al-Ramahi et al (2008)93 Jordan Case-control Convenience 19 W Infertility 
clinic
Women with TFI Endocervical NAAT 0
Al-Ramahi et al (2008)93 Jordan Case-control Convenience 38 W Infertility 
clinic
Women with male factor 
infertility
Endocervical NAAT 7·9%
Al-Ramahi et al (2008)93 Jordan Case-control Convenience 29 W Infertility 
clinic
Women with ovarian infertility Endocervical NAAT 3·4%
Al-Sweih et al (2012)100 Kuwait Case-control Convenience 127 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Semen NAAT 3·9%
Radouani et al (1998)106 Morocco Case-control Convenience 200 M Infertility 
clinic
Majority of men had male 
factor infertility
Serum MIF 
(unclear)
21·5%
Radouani et al (1998)106 Morocco Case-control Convenience 81 W Infertility 
clinic
Women with unclear infertility 
diagnosis
Serum MIF 
(unclear)
44·4%
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Al Subhi et al (2013)170 Oman Cross-sectional Convenience 51 W Infertility 
clinic
Women with TFI Endocervical EIA 5·9%
Al Subhi et al (2013)170 Oman Cross-sectional Convenience 167 W Infertility 
clinic
Women without TFI Endocervical EIA 4·8%
Qayum and Khalid-bin-
Saleem (2013)171
Pakistan Cross-sectional Convenience 80 W Gynaecology 
clinic
Women with unclear infertility 
diagnosis
Urine Unclear 7·5%
Al-Hindi et al (2010)172 Palestine Cross-sectional Convenience 69 W Infertility 
clinic
Women undergoing IVF in 
2000
Serum ELISA (IgM) 11·6%
Al-Hindi et al (2010)172 Palestine Cross-sectional Convenience 268 W Infertility 
clinic
Women undergoing IVF in 
2001
Serum ELISA (IgM) 23·9%
Al-Hindi et al (2010)172 Palestine Cross-sectional Convenience 316 W Infertility 
clinic
Women undergoing IVF in 
2002
Serum ELISA (IgM) 33·5%
Al-Hindi et al (2010)172 Palestine Cross-sectional Convenience 399 W Infertility 
clinic
Women undergoing IVF in 
2003
Serum ELISA (IgM) 9·3%
Al-Hindi et al (2010)172 Palestine Cross-sectional Convenience 586 W Infertility 
clinic
Women undergoing IVF in 
2004
Serum ELISA (IgM) 4·6%
Al-Hindi et al (2010)172 Palestine Cross-sectional Convenience 316 W Infertility 
clinic
Women undergoing IVF in 
2005
Serum ELISA (IgM) 2·8%
Abdul Jabbar (1990)173 Saudi 
Arabia
Cross-sectional Convenience 13 W Infertility 
clinic
Women with TFI Endocervical DFA 53·8%
Abdul Jabbar (1990)173 Saudi 
Arabia
Cross-sectional Convenience 18 W Infertility 
clinic
Women without TFI Endocervical DFA 11·1%
Abdul Jabbar (1990)173 Saudi 
Arabia
Cross-sectional Convenience 34 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Urethral DFA 26·4%
Alfarraj et al (2015)174 Saudi 
Arabia
Case-control Convenience 100 W Infertility 
clinic
Women with mixed infertility 
diagnosis
Endocervical NAAT 8·0%
Hossain (1988)115 Saudi 
Arabia
Cross-sectional Convenience 41 W Gynaecology 
clinic
Women with unclear infertility 
diagnosis
Endocervical Culture 9·5%
Hossain (1988)115 Saudi 
Arabia
Cross-sectional Convenience 41 W Gynaecology 
clinic
Women with unclear infertility 
diagnosis
Serum MIF (IgM) 0
Hossain (1988)115 Saudi 
Arabia
Cross-sectional Convenience 41 W Gynaecology 
clinic
Women with unclear infertility 
diagnosis
Serum MIF (IgG) 16·7%
Kamel (2013)116 Saudi 
Arabia
Randomised 
controlled trial‡
Convenience 640 W Gynaecology 
clinic
Women with unclear infertility 
diagnosis
Endocervical Culture 12·0%
Kamel (2013)116 Saudi 
Arabia
Randomised 
controlled trial‡
Convenience 640 W Gynaecology 
clinic
Women with unclear infertility 
diagnosis
Serum ELISA (IgA) 5%
Kamel (2013)116 Saudi 
Arabia
Randomised 
controlled trial‡
Convenience 640 W Gynaecology 
clinic
Women with unclear infertility 
diagnosis
Serum ELISA (IgG) 8·0%
Sabra and Al-Harbi 
(2014)175
Saudi 
Arabia
Cross-sectional Convenience 148 M Infertility 
clinic
Men with male factor 
infertility
Semen Giemsa 
stain
8·1%
Almroth et al (2005)123 Sudan Case-control Convenience 81 W Infertility 
clinic
More than half of women with 
TFI
Serum EIA (IgG) 14%
Alkayer et al (2017)125 Syria Case-control Convenience 23 W Hospital Women with mixed infertility 
diagnosis
Serum ELISA (IgG) 17·1%
Gdoura et al (2001a)176 Tunisia Cross-sectional Convenience 92 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Urethral NAAT 18·5%
Gdoura et al (2001b)177 Tunisia Cross-sectional Convenience 92 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Serum MIF (IgG) 9·8%
Gdoura et al (2001a)176 Tunisia Cross-sectional Convenience 92 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Urethral DFA 4·3%
Gdoura et al (2001a)176 Tunisia Cross-sectional Convenience 92 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Urethral Culture 1·1%
Gdoura et al (2001a)176 Tunisia Cross-sectional Convenience 92 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Urethral Unclear 8·7%
Gdoura et al (2001b)177 Tunisia Cross-sectional Convenience 92 W Infertility 
clinic
Partners of infertile men Endocervical NAAT 26·1%
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Gdoura et al (2001b)177 Tunisia Cross-sectional Convenience 92 W Infertility 
clinic
Partners of infertile men Serum MIF (IgG) 17·4%
Gdoura et al (2008)178 Tunisia Cross-sectional Convenience 104 M Infertility 
clinic
Men with male factor 
infertility
Urine NAAT 39·4%
Sellami et al (2014)179 Tunisia Cross-sectional Convenience 85 M Infertility 
clinic
Men with unclear infertility 
diagnosis
Semen NAAT 15·2%
Women with miscarriage (or abortion of unknown cause)
Zaki (1989)47 Egypt Cross-sectional Convenience 100 W Gynaecology 
clinic
Presenting with abortion Endocervical Culture 5%
Ahmadi et al (2016b)180 Iran Case-control Convenience 109 W Family 
planning 
clinic
Spontaneous abortion Endocervical NAAT 22·9%
Bagheri and Roghanian 
(2014)181
Iran Cross-sectional Convenience 70 W Hospital Recent or recurrent miscarriage Vaginal NAAT 1·4%
Bagheri et al (2018)53 Iran Case-control Convenience 97 W Fertility 
centre
Recent or recurrent miscarriage Vaginal NAAT 11·3%
Bagheri et al (2018)53 Iran Case-control Convenience 97 W Fertility 
centre
Recent or recurrent miscarriage Serum ELISA (IgA) 2·1%
Bagheri et al (2018)53 Iran Case-control Convenience 97 W Fertility 
centre
Recent or recurrent miscarriage Serum ELISA (IgG) 4·1%
Jahromi et al (2010)60 Iran Case-control Convenience 220 W Gynaecology 
clinic
Spontaneous abortion Endocervical DFA 25·5%
Massiha et al (2010)182 Iran Cross-sectional Convenience 84 W Hospital Presenting with abortion Unclear Unclear 2·3%
Salari and Badami 
(2002)183
Iran Case-control Convenience 125 W Hospital Recurrent abortion Endocervical DFA 7·2%
Sisakht et al (2017)76 Iran Case-control Convenience 77 W Gynaecology 
clinic
Spontaneous abortion Urine NAAT 9·3%
Zahirnia et al (2018)78 Iran Cross-sectional Convenience 124 W Gynaecology 
clinic
Presenting with abortion Vaginal NAAT 15·3%
Abdul-Karim et al (2009)80 Iraq Case-control Convenience 79 W Hospital Presenting with abortion Serum ELISA (IgG) 6·4%
Abdulkhudher et al 
(2014)79
Iraq Case-control Convenience 60 W Antenatal 
clinic
Recent or recurrent miscarriage Serum ELISA (IgM) 38·3%
Abdulkhudher et al 
(2014)79
Iraq Case-control Convenience 60 W Antenatal 
clinic
Recent or recurrent miscarriage Serum ELISA (IgG) 33·3%
Ahmed (2008)82 Iraq Case-control Convenience 60 W Hospital Recurrent miscarriage Serum ELISA 
(unclear)
0
Al-Husseinei et al (2009)84 Iraq Case-control Convenience 89 W Family 
planning 
clinic
Recent or recurrent abortion Endocervical ELFA 12·4%
Al-Husseinei et al (2009)84 Iraq Case-control Convenience 89 W Family 
planning 
clinic
Recent or recurrent abortion Serum IFAT 
(unclear)
14·6%
Alkhafaf (2013)86 Iraq Case-control Convenience 123 W Hospital Spontaneous abortion Serum ELISA (IgG) 17·1%
Al-Nuaimy and Al-Jandeel 
(2018)184
Iraq Case-control Convenience 120 W Hospital Recent or recurrent abortion Endocervical NAAT 17·5%
Al-Nuaimy and Al-Jandeel 
(2018)184
Iraq Case-control Convenience 120 W Hospital Recent or recurrent abortion Serum ELISA (IgG) 14·2%
Mohammed et al (2012)89 Iraq Case-control Convenience 62 W Gynaecology 
clinic
Three or more miscarriages Serum ELISA (IgM) 16·1%
Mohammed et al (2012)89 Iraq Case-control Convenience 34 W Gynaecology 
clinic
Less than three miscarriages Serum ELISA (IgM) 29·4%
Salman (2016)185 Iraq Cross-sectional Convenience 184 W Gynaecology 
clinic
Presenting with abortion Serum ELISA (IgM) 21·2%
Salman (2016)185 Iraq Cross-sectional Convenience 184 W Gynaecology 
clinic
Presenting with abortion Serum ELISA (IgG) 8·2%
Hossain (1988)115 Saudi 
Arabia
Cross-sectional Convenience 12 W Hospital Recurrent miscarriage Endocervical Culture 16·7%
(Table 2 continues on next page)
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High prevalence was observed in infertility clinic 
attendees, for both women and men (n=135), in which 
current infection prevalence ranged from 0 to 65·3% 
with a median of 9·2%, whereas ever infection prevalence 
ranged from 0 to 85·2% with a median of 18·6% 
(tables 2 and 3). Similarly, high prevalence was observed 
in women with miscarriage (n=27), in which current 
infection prevalence ranged from 1·4% to 25·5% with a 
median of 12·4%, whereas ever infection prevalence 
ranged from 4·1% to 33·3% with a median of 14·2% 
(tables 2 and 3).
Table 3 summarises the prevalence for other at­risk 
populations, and table 2 and the appendix (pp 9–14) 
include the full data.
The summarised and study­specific risk of bias and 
precision assessments are shown in the appendix 
(pp 15–27). Briefly, 166 (30·1%) of 552 prevalence mea­
sures were based on samples including 200 partici pants 
or more, and were classified as having higher precision. 
Although convenience sampling was the most common 
sampling methodology (495 [89·7%] of 552), probability­
based sampling methods, such as respondent­driven 
sampling, are of increasing use for populations at high 
risk (18 [45%] of 40 studies in female sex workers 
and men who have sex with men). Almost all studies 
(524 [94·9%] of 552) specified the type of biological 
assay used for infection ascertainment (low risk of bias 
for this domain). Response rate was, however, unclear 
for 417 (75·5%) of 552 studies. Prevalence studies were 
overall of reasonable quality; only eight (1·4%) of 552 had 
high risk of bias in two or more quality domains.
Table 3 shows the meta­analyses’ results for the pooled 
average C trachomatis prevalence for each at­risk popula­
tion, stratified by type of assay used for infection ascertain­
ment. Current infection prevalence was estimated at 3·0% 
(95% CI 2·3–3·8) in general populations, 2·8% (1·0–5·2) 
in populations at intermediate risk, 13·2% (7·2–20·7) in 
female sex workers, 1·2% (0·2–2·8) for genital infect­
ions and 7·7% (4·2–12·0) for rectal infections in men 
who have sex with men, 11·3% (9·0–13·7) in infertility 
clinic attendees, 12·4% (7·9–17·7) in women with mis­
carriage, 12·4% (9·4–15·7) in symptomatic women, and 
17·4% (12·5–22·8) in symptomatic men.
Meanwhile, pooled average prevalence of ever infection 
was estimated at 6·9% (4·3–10·0) in general populations, 
1·4% (0·8–2·4) in populations at intermediate risk, 
80·9% (43·8–100) in female sex workers, 21·5% (16·3–27·2) 
in infertility clinic attendees, 12·4% (6·6–19·5) in women 
with miscarriage, 37·1% (22·4–53·0) in women with 
ectopic pregnancy, 22·7% (15·4–31·0) in symptomatic 
women, and 16·9% (9·4–25·8) in symptomatic men 
(table 3).
Evidence for heterogeneity in C trachomatis prevalence 
estimates was observed; p values for Cochran’s Q statistic 
was <0·0001 in most meta­analyses (table 3). Prediction 
intervals were generally wide affirming high heterogeneity. 
I² was also mostly more than 70%, indicating that most 
variability is due to true differences in effect size across 
studies rather than chance.
Figures 2 and 3 and the appendix (pp 28–40) summarise 
the results of subgroup meta­analyses in various sub­
populations. These data show the results stratified by sex 
or by genital versus rectal infection (the latter only for 
men who have sex with men), for studies reporting 
current infection prevalence based on NAAT and those 
reporting ever infection prevalence, as well as by assay 
type for studies reporting current infection prevalence. 
Subgroup meta­analyses in infertile populations stratified 
by infertility diagnosis and by assay type are shown in the 
appendix (pp 41–42).
Country Study design Sampling* Sample 
size
Sex Study 
context
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Hossain (1988)115 Saudi 
Arabia
Cross-sectional Convenience 12 W Hospital Recurrent miscarriage Serum MIF (IgM) 0
Hossain (1988)115 Saudi 
Arabia
Cross-sectional Convenience 12 W Hospital Recurrent miscarriage Serum MIF (IgG) 16·7%
Women with ectopic pregnancy
Diab (1993)40 Egypt Case-control Convenience 30 W Family 
planning 
clinic
Ectopic pregnancy Serum EIA (IgG) 30%
Abdullah (2012)81 Iraq Case-control Convenience 24 W Hospital Ectopic pregnancy Serum ELISA (IgM) 4%
Abdullah (2012)81 Iraq Case-control Convenience 24 W Hospital Ectopic pregnancy Serum ELISA (IgG) 45%
DFA=direct fluorescent assay. EIA=enzyme immunoassay. ELFA=enzyme-linked fluorescence assay. IFAT=indirect fluorescent antibody test. M=men or sample predominantly of men. MIF=micro-immunofluorescence. 
NAAT=nucleic acid amplification test. NGOs=non-governmental organisations. STI=sexually transmitted infection. TFI=tubal factor infertility. W=women or sample predominantly of women. *Non-probability 
sampling refers to a sampling method in which the data collection process does not allow individuals to have equal chance of being selected; an example is convenience sampling for which individuals are selected on 
the basis of ease of accessibility (first-come first-served basis).127,128 Probability-based sampling refers to a sampling method in which data collection process is based on a random selection of study participants; an 
example is random sampling from a sampling frame.128 Another example of probability-based sampling is respondent-driven sampling, which is a sampling method specifically designed to sample hard-to-reach 
populations and is based on chain referral with the probability of selection calculated at each step in the network to produce adjusted prevalence estimates.129 †The decimal places of the prevalence measures are as 
reported in the original report, but prevalence figures with more than one decimal place were rounded to one decimal place. ‡The extracted prevalence measure is for the baseline measurement.
Table 2: Studies reporting Chlamydia trachomatis prevalence in populations at high risk, infertility clinic attendees, women with miscarriage, and women with ectopic pregnancy in the 
Middle East and north Africa
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Table 4 summarises results of the meta­regression 
analy ses. In the univariable analyses, at­risk population, 
assay type, sampling methodology, sample size, year of 
publicat ion, year of data collection, country, response rate, 
and sex were associated with prevalence at p≤0·2. 
Alignment with meta­regression underlying assumption 
Studies (n) Samples C trachomatis 
prevalence 
(median [range])
Pooled average 
C trachomatis prevalence 
(estimate [95% CI])
Heterogeneity measures
Tested C trachomatis 
positive
Q (p value)* I²† (95% CI) Prediction 
interval‡
General populations
Current genital infection
NAAT 48 25 397 748 2·9% (0–15·5) 3·1 (2·2–4·2) 714·3 (p<0·0001) 91·4% (89·4–93·0) 0·0–12·4
Culture 4 4464 55 5·8% (1·0–15·0) 4·3 (0·3–11·4) 22·5 (p<0·0001) 86·6% (67·7–94·5) 0·0–50·9
Other§ 23 128 013 328 3·5% (0–19·9) 2·4 (1·6–3·4) 722·3 (p<0·0001) 97·0% (96·2–97·5) 0·0–7·2
Overall current genital infection 75 157 874 1131 3·0% (0–19·9) 3·0 (2·3–3·8) 2703·5 (p<0·0001) 97·3% (96·9–97·6) 0·0–10·9
Anti-C trachomatis immunoglobulins
IgG (ever infection) 35 5877 525 4·7% (0–37·9) 6·9 (4·3–10·0) 226·1 (p<0·0001) 86·7% (82·2–90·1) 0·0–30·2
IgM (recent infection) 13 2843 74 1·6% (0–14·0) 1·8 (0·3–3·9) 77·7 (p<0·0001) 84·6% (75·1–90·4) 0·0–12·4
IgA 4 377 12 4·3% (0–40·4) 6·2 (0·0–21·6) 37·8 (p<0·0001) 92·1% (82·9–96·3) 0·0–93·7
Not specified (IgG, IgM, or IgA) 9 1081 61 4·5% (0–14·8) 4·3 (1·9–7·4) 34·5 (p<0·0001) 76·8% (55·7–87·8) 0·0–17·3
Unclear 1 250 8 ·· 3·2 (1·4–6·2) ·· ·· ··
Populations at intermediate risk
Current genital infection
NAAT 12 2815 69 1·5% (0–38·0) 2·6 (0·8–5·2) 117·4 (p<0·0001) 75·6% (56·0–86·5) 0·0–16·1
Culture ·· ·· ·· ·· ·· ·· ·· ··
Other§ 1 308 15 ·· 4·9 (2·8–7·9 ·· ·· ··
Overall current genital infection 13 3123 84 2·0% (0–38·0) 2·8 (1·0–5·2) 127·0 (p<0·0001) 90·6% (85·7–93·8) 0·0–15·8
Anti-C trachomatis immunoglobulins
IgG (ever infection) 1 1041 15 ·· 1·4 (0·8–2·4) ·· ·· ··
IgM (recent infection) ·· ·· ·· ·· ·· ·· ·· ··
IgA ·· ·· ·· ·· ·· ·· ·· ··
Not specified (IgG, IgM, or IgA) ·· ·· ·· ·· ·· ·· ·· ··
Unclear ·· ·· ·· ·· ·· ·· ·· ··
Populations at high risk
Female sex workers
Current genital infection
NAAT 12 4877 590 8·4% (0·9–72·9) 12·9 (6·5–21·0) 602·1 (p<0·0001) 98·2% (97·6–98·6) 0·0–52·0
Culture 1 116 8 ·· 6·9 (3·0–13·1) ·· ·· ··
Other§ 1 30 9 ·· 30·0 (14·7–49·4) ·· ·· ··
Overall current genital infection 14 5023 607 8·4% (0·9–72·9) 13·2 (7·2–20·7) 611·7 (p<0·0001) 97·9% (97·3–98·3) 0·0–50·9
Anti-C trachomatis immunoglobulins
IgG (ever infection) 4 472 364 90·0% (19·8–100) 80·9 (43·8–100·0) 209·9 (p<0·0001) 98·6% (97·7–99·1) 0·0–100·0
IgM (recent infection) 1 154 45 ·· 29·2 (22·2–37·1) ·· ·· ··
IgA ·· ·· ·· ·· ·· ·· ·· ··
Not specified (IgG, IgM, or IgA) 1 30 11 ·· 36·7 (19·9–56·1) ·· ·· ··
Unclear ·· ·· ·· ·· ·· ·· ·· ··
Men who have sex with men
Current genital infection
NAAT 12 2680 51 1·2% (0–8·8) 1·2 (0·2–2·8) 76·2 (p<0·0001) 85·6% (76·5–91·1) 0·0–9·5
Culture ·· ·· ·· ·· ·· ·· ·· ··
Other§ ·· ·· ·· ·· ·· ·· ·· ··
Current rectal infection
PCR 7 1506 129 6·3% (3·6–18·3) 7·7 (4·2–12·0) 40·6 (p<0·0001) 85·2% (71·5–92·3) 0·0–24·9
Overall current infection 19 4186 180 3·6% (0–18·3) 3·0 (1·2–5·4) 231·8 (p<0·0001) 92·2% (89·3–94·4) 0·0–17·9
(Table 3 continues on next page)
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Studies (n) Samples C trachomatis 
prevalence 
(median [range])
Pooled average 
C trachomatis prevalence 
(estimate [95% CI])
Heterogeneity measures
Tested C trachomatis 
positive
Q (p value)* I²† (95% CI) Prediction 
interval‡
(Continued from previous page)
Anti-C trachomatis immunoglobulins
IgG (ever infection) ·· ·· ·· ·· ·· ·· ·· ··
IgM (recent infection) ·· ·· ·· ·· ·· ·· ·· ··
IgA ·· ·· ·· ·· ·· ·· ·· ··
Not specified (IgG, IgM, or IgA) ·· ·· ·· ·· ·· ·· ·· ··
Unclear 1 2531 890 ·· 35·2 (33·3–37·1) ·· ·· ··
Infertility clinic attendees
Current genital infection
NAAT 37 4653 539 8·0% (0–39·4) 10·2 (7·5–13·1) 310·9 (p<0·0001) 88·4% (85·0–91·0) 0·1–31·0
Culture 7 1149 176 9·5% (1·1–65·3) 14·4 (4·8–27·7) 140·8 (p<0·0001) 95·7% (93·3–97·3) 0·0–69·2
Other§ 20 1844 203 10·2% (3·0–53·8) 12·3 (8·5–16·5) 112·8 (p<0·0001) 83·2% (75·1–88·6) 0·5–33·7
Overall current genital infection 64 7646 918 9·2% (0–65·3) 11·3 (9·0–13·7) 574·9 (p<0·0001) 89·0% (86·7–90·9) 0·2–33·3
Anti-C trachomatis immunoglobulins
IgG (ever infection) 37 3608 689 18·6% (0–85·2) 21·5 (16·3–27·2) 531·8 (p<0·0001) 93·2% (91·6–94·6) 0·2–59·7
IgM (recent infection) 17 3145 332 4·6% (0–86·7) 10·2 (5·0–16·8) 435·4 (p<0·0001) 96·3% (95·2–97·2) 0·0–47·0
IgA 6 2302 82 3·6% (0–5·0) 1·8 (0·1–4·7) 54·4 (p<0·0001) 90·8% (82·8–95·1) 0·0–16·4
Not specified (IgG, IgM, or IgA) 5 760 211 23·2% (11·1–44·4) 26·1 (17·9–35·3) 27·5 (p<0·0001) 85·4% (67·8–93·4) 2·6–61·8
Unclear 6 430 73 14·8% (3·3–33·0) 14·9 (7·0–24·8) 30·0 (p<0·0001) 83·3% (65·1–92·0) 0·0–53·3
Women with miscarriage
Current genital infection
NAAT 6 597 87 13·3% (1·4–22·9) 12·9 (7·4–19·5) 24·4 (p=0·0002) 79·5% (55·3–90·6) 0·1–38·9
Culture 2 112 7 10·9% (5·0–16·7) 7·1 (0·0–21·8) 2·1 (p=0·1483) 52·1% (0·0–88·0) ··
Other§ 3 434 76 12·4% (7·2–25·5) 14·4 (4·9–27·6) 21·9 (p<0·0001) 90·8% (76·1–96·5) 0·0–100·0
Overall current genital infection 11 1143 170 12·4% (1·4–25·5) 12·4 (7·9–17·7) 58·0 (p<0·0001) 82·8% (70·5–89·9) 0·6–34·3
Anti-C trachomatis immunoglobulins
IgG (ever infection) 7 675 84 14·2% (4·1–33·3) 12·4 (6·6–19·5) 33·5 (p<0·0001) 82·1% (64·2–91·0) 0·0–39·6
IgM (recent infection) 5 352 82 21·2% (0–38·3) 21·2 (11·9–32·2) 16·2 (p=0·0028) 75·3% (39·1–89·9) 0·0–61·8
IgA 1 97 2 ·· 2·1 (0·3–7·3) ·· ·· ··
Not specified (IgG, IgM, or IgA) 2 149 13 7·3% (0–14·6) 4·7 (0·0–27·9) 16·1 (p<0·0001) 93·8% (80·0–98·1) ··
Unclear 1 84 2 ·· 2·3 (0·3–8·3) ·· ·· ··
Women with ectopic pregnancy
Current genital infection
NAAT ·· ·· ·· ·· ·· ·· ·· ··
Culture ·· ·· ·· ·· ·· ·· ·· ··
Other§ ·· ·· ·· ·· ·· ·· ·· ··
Overall current genital infection ·· ·· ·· ·· ·· ·· ·· ··
Anti-C trachomatis immunoglobulins
IgG (ever infection) 2 54 20 37·5% (30·0–45·0) 37·1 (22·4–53·0) 1·4 (p=0·2418) 27·0% ··
IgM (recent infection) 1 24 1 ·· 4·2 (0·1–21·1) ·· ·· ··
IgA ·· ·· ·· ·· ·· ·· ·· ··
Not specified (IgG, IgM, or IgA) ·· ·· ·· ·· ·· ·· ·· ··
Unclear ·· ·· ·· ·· ·· ·· ·· ··
Symptomatic women
Current genital infection
NAAT 49 14 398 1123 8·0% (0–68·0) 8·8 (6·2–11·7) 1506·7 (p<0·0001) 96·8% (96·3–97·3) 0·0–35·4
Culture 10 2951 752 12·9% (0·7–69·4) 18·9 (4·1–40·9) 1511·1 (p<0·0001) 99·4% (99·3–99·5) 0·0–97·2
Other§ 31 4796 729 14·7% (0–89·3) 16·8 (11·6–22·7) 723·8 (p<0·0001) 95·9% (94·9–96·6) 0·0–55·4
(Table 3 continues on next page)
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of normal ran dom effects was confirmed through normal 
probability plots (appendix p 43).186 Graphical illustrations 
of the fitted regression line for year of publication and year 
of data collection are shown in the appendix (p 44). Only 
at­risk popula tion, assay type, sample size, country, and 
sex remained associated with C trachomatis prevalence in 
a multi variable model. No evidence was found for a 
temporal variation in prevalence (p=0·281 for year of 
publication), for sampling methodology (p=0·347), or for 
response rate (p=0·237). This model explained 29·0% of 
prevalence variation.
Relative to general populations, the adjusted odds 
ratio (aOR) was 11·28 (95% CI 5·78–22·01) for female 
sex work ers, 7·17 (4·05–12·68) for symptomatic men, 
4·93 (1·03–23·52) for women with ectopic pregnancy, 
4·16 (1·72–10·08) for men who have sex with 
men, 3·39 (2·41–4·77) for infertility clinic attendees, 3·47 
(2·47–4·87) for symptomatic women, 2·78 (1·57–4·93) 
for women with miscarriage, and 1·81 (0·79–4·13) for 
popula tions at intermediate risk. Other factors associated 
with C trachomatis prevalence were women versus men 
(aOR 1·61, 95% CI 1·05–2·46), Pakistan versus other 
Middle East or north African countries (0·39, 0·22–0·69), 
ever infection (anti­C trachomatis IgG; 2·17, 1·54–3·06) 
and current infection prevalence using assays other than 
NAAT or culture versus NAAT (1·47, 1·02–2·13), and 
studies with higher (≥200 participants) versus lower 
precision (0·63, 0·48–0·83).
Discussion
We provided a comprehensive assessment of C trachomatis 
epidemiology in the Middle East and north Africa.2,3 
Unexpectedly, given this region’s sexually conservative 
norms and low observed levels of several viral STIs,10,11,187–189 
C trachomatis current infection prevalence was 3% in the 
population at large, similar to WHO prevalence estimates 
for this region of about 3% in 20123 and about 3∙5% in 
2016.190 The prevalence was also in line with WHO 
estimates for the Western Pacific region (about 4%) and 
European region (about 3%),190 where broad C trachomatis 
control programmes, including opportunistic testing, are 
stand ard in some high­income countries,191–193 but higher 
than that for South­east Asia region (about 1∙5%) and 
lower than that for the African region (about 5%) and 
the region of the Americas (about 5∙5%).190 This high 
prevalence suggests substantial infection and disease 
burden that needs to be tackled through sexual health and 
STI­specific programmes, for both women and men. 
Although these findings were based on a volume of 
epidemiological evidence, most studies used conve nience 
Studies (n) Samples C trachomatis 
prevalence 
(median [range])
Pooled average 
C trachomatis prevalence 
(estimate [95% CI])
Heterogeneity measures
Tested C trachomatis 
positive
Q (p value)* I²† (95% CI) Prediction 
interval‡
(Continued from previous page)
Overall current genital infection 90 22 145 2604 11·7% (0–89·3) 12·4 (9·4–15·7) 4323·7 (p<0·0001) 97·9% (97·7–98·1) 0·0–52·3
Anti-C trachomatis immunoglobulins
IgG (ever infection) 23 2377 609 18·2% (2·7–86·0) 22·7 (15·4–31·0) 454·1 (p<0·0001) 95·2% (93·8–96·2) 0·0–67·9
IgM (recent infection) 9 1042 160 3·1% (0–86·0) 13·9 (1·9–33·6) 452·7 (p<0·0001) 98·2% (97·6–98·7) 0·0–91·3
IgA 5 365 93 12·5% (3·7–59·6) 24·9 (6·6–49·6) 98·9 (p<0·0001) 96·0% (93·0–97·7) 0·0−100·0
Not specified (IgG, IgM, or IgA) 7 2530 761 15·0% (11·6–46·6) 23·5 (11·1–38·7) 346·8 (p<0·0001) 98·3% (97·6–98·4) 0·0−80·0
Unclear 6 943 83 7·7% (1·7–30·0) 8·7 (4·3–14·4) 32·2 (p<0·0001) 84·5% (67·9–92·5) 0·0–32·6
Symptomatic men
Current genital infection
NAAT 14 7160 726 12·2% (4·2–33·3) 13·9 (8·3–20·6) 488·7 (p<0·0001) 97·3% (96·5–98·0) 0·0–46·4
Culture 5 4744 75 9·3% (0·4–19·6) 8·7 (1·1–21·7) 147·5 (p<0·0001) 97·3% (95·6–98·3) 0·0–72·7
Other§ 13 2499 355 27·6% (4·7–52·0) 26·3 (15·3–39·1) 351·7 (p<0·0001) 96·6% (95·4–97·5) 0·0–78·9
Overall current genital infection 32 14 403 1156 15·5% (0·4–52·0) 17·4 (12·5–22·8) 1628·1 (p<0·0001) 98·1% (97·8–98·4) 0·0–53·3
Anti-C trachomatis immunoglobulins
IgG (ever infection) 8 831 164 14·4% (5·1–46·0) 16·9 (9·4–25·8) 69·6 (p<0.0001) 89·9% (82·6–94·2) 0·0–52·8
IgM (recent infection) 3 330 24 3·9% (2·8–12·2) 6·0 (1·4–13·0) 9·3 (p=0·0095) 78·5% (31·0–93·3) 0·0–100·0
IgA ·· ·· ·· ·· ·· ·· ·· ··
Not specified (IgG, IgM, or IgA) 5 1596 687 46·0% (10·0–49·1) 35·6 (18·5–54·9) 143·3 (p<0·0001) 97·2% (95·4–98·3) 0·0–97·3
Unclear 8 4876 233 14·3% (1·6–76·9) 24·0 (9·2–42·8) 498·1 (p<0·0001) 98·6% (98·1–99·0) 0·0–90·3
A minimum of two studies was necessary to do a meta-analysis. The same population might have contributed different measures for both current and ever infection with C trachomatis. NAAT=nucleic acid 
amplification test. *Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size of C trachomatis prevalence across studies. †I² is a measure assessing the magnitude of between-study 
variation that is due to differences in effect size of C trachomatis prevalence across studies rather than chance. ‡Prediction interval is a measure estimating the 95% CI of the distribution of true effect sizes of 
C trachomatis prevalence measures. §Other assays detecting current infection such as direct fluorescence assays, Giemsa staining, and enzyme-linked immunoassays applied to genital samples.
Table 3: Results of meta-analyses on studies reporting Chlamydia trachomatis prevalence in the Middle East and north Africa stratified by at-risk population and C trachomatis ascertainment
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sampling (about 90%) or had unclear response rate 
(>75%). Meta­regression, however, did not identify an 
effect for these factors on observed prevalence. A 
summary of this study and its results in Arabic language 
can be found in the appendix (p 4).
Although infection prevalence in the population at large 
suggests active transmission networks for C trachomatis 
and other STIs, it might not necessarily reflect prevalent 
sexual risk behaviours. This outcome might reflect, at least 
in part, poor access to and utilisation of STI services—
there is very limited capacity in the Middle East and north 
Africa for STI prevention and treatment, not to mention 
C trachomatis screening and broader sexual health 
programmes. As observed elsewhere, such as in Alaskan 
Eskimo populations194 and populations in South Pacific 
Islands,195 poor C trachomatis diagnosis and specific 
treatment can result in unusually high prevalence,194,196 
probably because C trachomatis is largely asymptomatic,4 
and if untreated, shedding can persist even for years,197 
thereby increasing the potential for reinfection within 
couples198 and for transmission in the population.
The high prevalence found in populations at high risk 
such as female sex workers, in context of evidence 
suggesting strong partial immunity against reinfection,199 
is consistent with the important role of commercial 
sex networks in infection transmission. Independent 
evidence supports existence of hidden pockets of high 
sexual­risk behaviour driving STI incidence in the 
Middle East and north Africa.10,11 Among male STI 
patients, 77% in Kuwait200 and 80% in Somalia201 reported 
paying a female sex worker for sex, and among migrant 
workers in Pakistan 22% reported sex with a female sex 
worker.202 Higher levels of sexual­risk behaviour and 
emerging HIV epidemics have been also documented 
among men who have sex with men, male sex 
workers, and male­to­female transgenders in systematic 
reviews.17,203 Sexual networks, however, remain poorly 
investigated in the Middle East and north Africa, owing 
to cultural sensitivities.
The possible role of C trachomatis infection in poor 
reproductive health outcomes remains unappreciated and 
neglected by the public health establishment in the 
Middle East and north Africa, despite substantial social 
and economic implications for women and their fam­
ilies.204,205 A main finding of this study is the high current 
C trachomatis infection prevalence in infertility clinic 
attendees, with odds of infection three­times higher than 
in the general population. By contrast, studies among 
infertility clinic attendees in Europe usually show that 
current C trachomatis infection is uncommon, but 
serological evidence of past infection, assumed to have 
resulted in fallopian tube scarring, is common.206–209 This 
finding suggests a role for C trachomatis in infertility in the 
Middle East and north Africa. Indeed, this region appears 
to have the highest rate of primary infertility worldwide, 
which remains unexplained.12 The Middle East and north 
Africa is also a region where infertility has multiple 
detrimental sociocultural consequences,210 and where 
several countries have had rapidly declin ing fertility rates 
to even below replacement level.211,212 The prevalence of 
current C trachomatis infection was also high in women 
Figure 2: Meta-analysis of studies reporting Chlamydia trachomatis current infection prevalence assessed 
using nucleic acid amplification test in the general population in the Middle East and north Africa
Data are stratified by sex. Error bars are 95% CIs.
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with miscarriage and in pregnant women—similar to that 
found in pregnant women in low­income and middle­
income countries elsewhere.213–217 This stigmatised and 
largely asymptomatic infection might not be visible to the 
public eye, but its reproductive health sequelae are visible, 
even if not explicitly linked to the underlying cause.
C trachomatis prevalence in women was higher than in 
men (two­times higher odds). This difference possibly 
reflects a longer duration of infection for women, 
considering that infection in men is more symptomatic218 
(nearly two­times higher prevalence in symptomatic men 
than in symptomatic women), and therefore more likely 
to be treated. Ever infection (anti­C trachomatis IgG) 
prevalence was two­times higher than current infection 
prevalence, but the epidemiological relevance of ever 
infection prevalence might be limited given challenges 
in C trachomatis serology interpretation.219
The Middle East and north Africa is burdened by 
C trachomatis infection, but the public health response 
remains rudimentary and far from achieving WHO’s 
Global Health Sector Strategy on STIs.8 Evidence for 
some differences in C trachomatis prevalence by country 
has been reported, but remarkably, no evidence was 
found for a variation in prevalence over time (1982–2018). 
Lingering STI stigma prevents those infected from 
accessing proper health care, including those most at 
risk. The role of screening and treatment for asymptomatic 
C trachomatis within established programmes, such as for 
family planning, primary health care, or HIV, needs 
careful consideration given the cost and uncertain effect 
on prevalence at modest levels of uptake.220
Current STI surveillance focused on inefficient routine 
case reporting is not capturing the reality of the trans­
mission dynamics.221 Although routine case reporting 
could be improved with more consistency and universality 
in reporting and emphasis on aetiological approaches,221 
its usefulness for a robust long­term evaluation of 
infection trends is rather limited. Sentinel surveillance of 
different at­risk populations should be explored, as 
recommended by the WHO Global Health Sector Strategy 
on STIs,8 to better identify outbreaks or emerging 
epidemics, strategically direct resources for prevention, 
treatment, and control, and monitor and evaluate STI 
programmes.1 The recent progress in HIV surveillance in 
the Middle East and north Africa, in the form of repeated 
rounds of HIV­integrated biobehavioural sur veillance 
surveys,222,223 should be extended to STIs.221,224
Our study has important but unavoidable limitations. 
Quantity and quality of available data varied by country 
and population, particularly for populations at high risk 
where most data came from only a few countries—
eg, most studies of men who have sex with men were from 
Pakistan. No data were identified for Afghanistan, Bahrain, 
Libya, and Yemen. Prevalence levels might not have been 
strictly representative and might have been affected by 
publication bias, as suggested by the small­study effect 
observed. Studies in women with miscarriage might have 
included women with induced abortions; however, these 
were not explicitly indicated, possibly for legal reasons, as 
abortion is illegal in most of the Middle East and north 
Africa.225,226 The wide array of diagnostics used for 
ascertainment might have also introduced detection bias.
Factors that might have contributed to differences in 
C trachomatis positivity rates across studies include 
sampling variation and potential selection bias, spatial 
or temporal variability in prevalence, and possibly 
unreported underlying comorbidities. This study did not 
assess other STIs that might have also contributed to 
infertility, pregnancy­related morbidity, and other health 
conditions in women with C trachomatis infection. Such 
Figure 3: Meta-analysis of studies reporting Chlamydia trachomatis current infection prevalence assessed using 
nucleic acid amplification test in infertility clinic attendees in the Middle East and north Africa
Data are stratified by sex. Error bars are 95% CIs.
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potential biases might have contributed to some of the 
unexplained heterogeneity observed in the prevalence 
levels. Given potential limitations in the representativeness 
of the prevalence measures as well as heterogeneity 
across studies, the calculated pooled prevalence should 
be interpreted as a pooled average, rather than strictly 
Studies (n) Samples (n) Univariable analyses Variance 
explained R²
Multivariable analysis
OR (95% CI) p value LR test 
p value*
Adjusted OR (95% CI) p value LR test 
p value†
At-risk population
General populations 137 168 302 1·00 (ref) ·· <0·0001 19·0% 1·00 (ref) ·· <0·0001
Populations at intermediate risk 14 4164 0·70 (0·32–1·54) 0·374 ·· ·· 1·81 (0·79–4·13) 0·157 ··
Female sex workers 20 5679 8·99 (4·57–17·71) <0·0001 ·· ·· 11·28 (5·78–22·01) <0·0001 ··
Men who have sex with men 20 6717 0·83 (0·42–1·64) 0·591 ·· ·· 4·16 (1·72–10·08) 0·002 ··
Infertility clinic attendees 135 17 891 3·77 (2·67–5·31) <0·0001 ·· ·· 3·39 (2·41–4·77) <0·0001 ··
Women with miscarriage 27 2500 3·53 (1·94–6·40) <0·0001 ·· ·· 2·78 (1·57–4·93) 0·001 ··
Women with ectopic pregnancy 3 78 8·25 (1·58–43·08) 0·012 ·· ·· 4·93 (1·03–23·52) 0·045 ··
Symptomatic women 140 29 402 3·74 (2·66–5·26) <0·0001 ·· ·· 3·47 (2·47–4·87) <0·0001 ··
Symptomatic men 56 22 036 5·76 (3·68–9·03) <0·0001 ·· ·· 7·17 (4·05–12·68) <0·0001 ··
Assay type
NAAT (current infection) 197 64 083 1·00 (ref) ·· <0·0001 7·1% 1·00 (ref) ·· <0·0001
Culture (current infection) 29 13 536 1·92 (1·05–3·50) 0·034 ·· ·· 1·10 (0·62–1·95) 0·742 ··
Other (current infection)‡ 92 137 924 1·90 (1·30–2·79) 0·001 ·· ·· 1·47 (1·02–2·13) 0·041 ··
Anti-C trachomatis immunoglobulins§
IgG (ever infection) 117 14 935 2·99 (2·10–4·26) <0·0001 ·· ·· 2·17 (1·54–3·06) <0·0001 ··
IgM (recent infection) 49 7890 1·17 (0·72–1·90) 0·517 ·· ·· 0·90 (0·57–1·40) 0·627 ··
IgA 16 3141 0·92 (0·42–2·02) 0·836 ·· ·· 0·78 (0·39–1·56) 0·481 ··
Not specified (IgG, IgM, or IgA) 29 6146 2·81 (1·54–5·13) 0·001 ·· ·· 2·25 (1·28–3·97) 0·005 ··
Unclear 23 9114 2·53 (1·30–4·94) 0·007 ·· ·· 1·49 (0·81–2·75) 0·200 ··
Sampling methodology¶
Non-probability-based sampling 495 227 208 1·00 (ref) ·· <0·0001 3·5% 1·00 (ref) ·· 0·347
Probability-based sampling 57 29 561 0·37 (0·24–0·56) <0·0001 ·· ·· 0·80 (0·50–1·27) 0·347 ··
Sample size
<200 386 32 782 1·00 (ref) ·· <0·0001 6·0% 1·00 (ref) ·· 0·001
≥200 166 223 987 0·42 (0·32–0·56) <0·0001 ·· ·· 0·63 (0·48–0·83) 0·001 ··
Response rate
≥80% 112 38 732 1·00 (ref) ·· 0·187 0·1% 1·00 (ref) ·· 0·237
<80% or unclear 440 218 037 0·80 (0·57–1·12) 0·187 ·· ·· 0·83 (0·61–1·13) 0·237 ··
Year of publication|| 552 256 769 0·96 (0·95–0·98) <0·0001 <0·0001 4·4% 0·99 (0·98–1·01) 0·281 0·281
Year of data collection 552 256 769 0·96 (0·95–0·98) <0·0001 <0·0001 4·2% ·· ·· ··
Country
Other Middle East or north 
African countries
245 189 529 1·00 (ref) ·· <0·0001 5·2% 1·00 (ref) ·· 0·013
Egypt 89 7434 1·58 (1·08–2·31) 0·018 ·· ·· 1·05 (0·73–1·51) 0·774 ··
Iran 176 38 647 0·80 (0·59–1·08) 0·145 ·· ·· 0·90 (0·68–1·19) 0·472 ··
Pakistan 42 21 159 0·31 (0·19–0·52) <0·0001 ·· ·· 0·39 (0·22–0·69) 0·002 ··
Sex
Men 133 42 393 1·00 (ref) ·· 0·131 0·2% 1·00 (ref) ·· 0·029
Women 419 214 376 1·27 (0·93–1·74) 0·131 ·· ·· 1·61 (1·05–2·46) 0·029 ··
Adjusted R² in the final multivariable model was 29·0%. LR=likelihood ratio. NAAT=nucleic acid amplification test. OR=Odds ratio. *Predictors with p≤0·2 in the univariable model were considered significant. †Predictors 
with p≤0·05 in the multivariable model were considered significant. ‡Other assays detecting current infection such as direct fluorescence assays, Giemsa staining, and enzyme-linked immunoassays applied to genital 
samples. §Includes assays such as enzyme-linked immunoassay and micro-immunofluorescence. ¶Non-probability sampling refers to a sampling method in which the data collection process does not allow individuals 
to have equal chance of being selected; an example is convenience sampling for which individuals are selected on the basis of ease of accessibility (first-come first-served basis).127,128 Probability-based sampling refers to 
a sampling method in which data collection process is based on a random selection of study participants; an example is random sampling from a sampling frame.128 Another example of probability-based sampling is 
respondent-driven sampling, which is a sampling method specifically designed to sample hard-to-reach populations and is based on chain referral with the probability of selection calculated at each step in the network 
to produce adjusted prevalence estimates.129 ||Only year of publication was considered for the multivariable meta-regression analysis because of collinearity with year of data collection.
Table 4: Results of meta-regressions to identify associations and sources of between-study heterogeneity for Chlamydia trachomatis prevalence in the Middle East and north Africa
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an estimate of the mean prevalence in the considered 
population or subpopulation.
In conclusion, C trachomatis current infection pre­
valence in the population at large in the Middle East and 
north Africa is at 3%, similar to other regions, but 
higher than expected given these countries’ sexually 
conservative norms. The high prevalence (>10%) in 
infertility clinic attendees and in women with misc­
arriage, provides suggestive evidence for the potential 
role of C trachomatis in poor reproductive outcomes in 
the Middle East and north Africa. In the context of very 
limited programming for sexual health and STIs, our 
findings highlight an important, yet neglected and 
poorly recognised infection and disease burden, despite 
the social and economic impact. There is an urgent 
need for targeted and culturally appropriate pro­
grammes promot ing sexual health for different at­risk 
populations. Tackling this infection with appropriate 
interventions is essential to control disease sequelae, 
to address the WHO Global Health Sector Strategy 
on STIs,8 and to accomplish key health Sustainable 
Development Goals.
Contributors
AS contributed to the study design, did the systematic searches of the 
literature, selection of studies for inclusion, and the data extraction and 
data analyses. HC contributed to the study design, double extracted the 
data, updated the systematic review, and did the data analyses. AS and 
HC wrote the first draft of the paper. JGH contributed to identification of 
unpublished data. NL contributed to the data extraction, analyses, and 
drafting of the Article. LJA­R conceived and led the design of the study, 
data extraction, data analyses, and drafting of the Article. All authors 
contributed to discussion and interpretation of the results and to the 
writing of the manuscript. All authors have read and approved the final 
manuscript.
Declaration of interests
We declare no competing interests.
Acknowledgments
This study was funded by the National Priorities Research Program 
(grant number 9­040­3­008) from the Qatar National Research Fund 
(a member of Qatar Foundation). Infrastructure support was provided 
by the Biostatistics, Epidemiology, and Biomathematics Research Core 
at Weill Cornell Medicine­Qatar, Cornell University, Qatar 
Foundation–Education City, Doha, Qatar. The statements made herein 
are solely the responsibility of the authors. The publication of this 
Article was funded by the Qatar National Library. We thank Adona 
Canlas and Ashwini Deshmukh for their assistance with locating 
full­text articles, and Ghina Mumtaz and Vajiheh Akbarzadeh for their 
assistance with translating manuscripts from foreign languages.
References
1 WHO. Baseline report on global sexually transmitted infection 
surveillance 2012. Geneva: World Health Organization, 2013. 
http://www.who.int/reproductivehealth/publications/
rtis/9789241505895/en/ (accessed March 9, 2014).
2 Holmes KK. Sexually transmitted diseases, 4th edn. New York: 
McGraw­Hill Medical, 2008.
3 Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of 
the prevalence and incidence of four curable sexually transmitted 
infections in 2012 based on systematic review and global reporting. 
PLoS One 2015; 10: e0143304.
4 WHO. Global prevalence and incidence of selected curable sexually 
transmitted infections: overview and estimates. Geneva: World 
Health Organization, 2001.
5 Mishori R, McClaskey EL, WinklerPrins VJ. Chlamydia trachomatis 
infections: screening, diagnosis, and management. 
Am Fam Physician 2012; 86: 1127–32.
6 Rekart ML, Gilbert M, Meza R, et al. Chlamydia public health 
programs and the epidemiology of pelvic inflammatory disease and 
ectopic pregnancy. J Infect Dis 2013; 207: 30–38.
7 UN General Assembly. Transforming our world: the 2030 Agenda 
for Sustainable Development. 2015. https://sustainabledevelopment.
un.org/content/documents/21252030%20Agenda%20for%20
Sustainable%20Development%20web.pdf (accessed June 6, 2017).
8 WHO. Global health sector strategy on sexually transmitted 
infections, 2016–2021. Geneva: World Health Organization, 2016.
9 Abu­Raddad LJ, Ghanem KG, Feizzadeh A, Setayesh H, Calleja JM, 
Riedner G. HIV and other sexually transmitted infection research 
in the Middle East and north Africa: promising progress? 
Sex Transm Infect 2013; 89 (suppl 3): iii1–4.
10 Abu­Raddad LJ, Hilmi N, Mumtaz G, et al. Epidemiology of HIV 
infection in the Middle East and north Africa. AIDS 2010; 
24 (suppl 2): S5–23.
11 Abu­Raddad LJ, Akala FA, Semini I, Riedner G, Wilson D, Tawil O. 
Characterizing the HIV/AIDS epidemic in the Middle East and 
north Africa: time for strategic action. Middle East and North Africa 
HIV/AIDS Epidemiology Synthesis Project. Washington DC: 
The World Bank Press, 2010.
12 Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, 
Stevens GA. National, regional, and global trends in infertility 
prevalence since 1990: a systematic analysis of 277 health surveys. 
PLoS Med 2012; 9: e1001356.
13 Higgins JPT, Green S, Cochrane Collaboration. Cochrane handbook 
for systematic reviews of interventions. Chichester: Wiley­Blackwell, 
2008.
14 Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred 
reporting items for systematic reviews and meta­analyses: 
the PRISMA statement. PLoS Med 2009; 6: e1000097.
15 International AIDS Society. Abstract archives of international aids 
society conferences. 2016. http://www.abstract­archive.org/ 
(accessed July 17, 2017).
16 Abu­Raddad LJ, World Bank. Characterizing the HIV/AIDS 
epidemic in the Middle East and north Africa: time for strategic 
action. Washington DC: World Bank, 2010.
17 Mumtaz G, Hilmi N, McFarland W, et al. Are HIV epidemics 
among men who have sex with men emerging in the Middle East 
and north Africa? A systematic review and data synthesis. PLoS Med 
2010; 8: e1000444.
18 Mumtaz GR, Weiss HA, Thomas SL, et al. HIV among people who 
inject drugs in the Middle East and north Africa: systematic review 
and data synthesis. PLoS Med 2014; 11: e1001663.
19 Harfouche M, Chemaitelly H, Mahmud S, et al. Epidemiology of 
hepatitis C virus among hemodialysis patients in the Middle East 
and north Africa: systematic syntheses, meta­analyses, 
and meta­regressions. Epidemiol Infect 2017; 145: 3243–63.
20 Mahmud S, Al­Kanaani Z, Chemaitelly H, Chaabna K, 
Kouyoumjian SP, Abu­Raddad LJ. Hepatitis C virus genotypes in 
the Middle East and north Africa: distribution, diversity, 
and patterns. J Med Virol 2018; 90: 131–41.
21 Harfouche M, Chemaitelly H, Kouyoumjian SP, et al. Hepatitis C 
virus viremic rate in the Middle East and north Africa: systematic 
synthesis, meta­analyses, and meta­regressions. PLoS One 2017; 
12: e0187177.
22 Chemaitelly H, Mahmud S, Chaabna K, Kouyoumjian SP, 
Mumtaz GR, Abu­Raddad LJ. The epidemiology of hepatitis C virus 
in the World Health Organization Eastern Mediterranean region: 
implications for strategic action. 2019. World Health Organization 
Report (in press).
23 El­Kettani A, Mahiane G, Bennani A, et al. Trends in adult 
chlamydia and gonorrhea prevalence, incidence and urethral 
discharge case reporting in Morocco over 1995–2015: estimates 
using the spectrum­sexually transmitted infection model. 
Sex Transm Infect 2017; 44: 557–64.
24 Smolak A, Rowley J, Nagelkerke N, et al. Trends and predictors of 
syphilis prevalence in the general population: global pooled 
analyses of 1103 prevalence measures including 136 million syphilis 
tests. Clin Infect Dis 2018; 66: 1184–91.
25 Korenromp EL, Mahiane G, Rowley J, et al. Estimating prevalence 
trends in adult gonorrhoea and syphilis in low­ and middle­income 
countries with the spectrum­STI model: results for Zimbabwe and 
Morocco from 1995 to 2016. Sex Transm Infect 2017; 93: 599–606.
Articles
www.thelancet.com/lancetgh   Vol 7   September 2019 e1221
26 Freeman MF, Tukey JW. Transformations related to the angular and 
the square root. Ann Math Stat 1950; 21: 607–11.
27 Miller JJ. The inverse of the Freeman–Tukey double arcsine 
transformation. Am Stat 1978; 32: 138.
28 Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta­analysis of 
prevalence. J Epidemiol Community Health 2013; 67: 974–78.
29 DerSimonian R, Laird N. Meta­analysis in clinical trials. 
Control Clin Trials 1986; 7: 177–88.
30 Borenstein M. Introduction to meta­analysis. Chichester: John Wiley 
& Sons, 2009.
31 Higgins JP, Thompson SG. Quantifying heterogeneity in a 
meta­analysis. Stat Med 2002; 21: 1539–58.
32 R core team. R: a language and environment for statistical 
computing. Vienna: R Foundation for Statistical Computing, 2017.
33 UN Population Division. World population prospects 2017. 2018. 
https://population.un.org/wpp/ (accessed July 10, 2018).
34 StataCorp. Stata statistical software: release 14. College Station: 
StataCorp LP, 2014.
35 Kadi Z, Bouguermouh A, Djenaoui T, Allouache A, Dali S, Hadji N. 
Chlamydial genital infection in Algiers: a sero­epidemiological 
survey. Trans R Soc Trop Med Hyg 1990; 84: 863–65.
36 Abdel Monem AA, Bassyouni MI, Soliman MY, Ahmed SR, 
Abdel Hafeez HA. Chlamydia trachomatis antigen detection in 
female infertility. El-Minia Med Bull 2005; 16: 104–12.
37 Aboul Atta HNE, Ibrahem AA. Role of chlamydia and mycoplasma 
in the etiology of non­gonococcal urethritis in men. 
Egypt J Med Microbiol 1995; 4: 355–60.
38 Badary MS. Study of the role of cervical chlamydial infection in 
unexplained infertility and mucopurulent cervicitis. 
Egypt J Med Microbiol 1996; 5: 431–38.
39 Berry ME, El Shabrawy A. Chlamydia trachomatis infection and 
relation to female infertility. Egypt J Med Microbiol 1996; 5: 297–304.
40 Diab KM. Gonococcal and chlamydial antibodies in Egyptian 
women with ectopic pregnancy. New Egypt J Med 1993; 8: 1006–10.
41 Draz EI, Hassan AM, Khalil HS, Elomary MA. Evaluation of pelvic 
inflammatory disease potential in cholinesterase inhibitor 
pesticide­exposed females. Environ Sci Pollut Res Int 2018; 
25: 30818–25.
42 El­Sayed N, Abdallah M, Abdel Mobdy A, et al. Evaluation of 
selected reproductive health infections in various Egyptian 
population groups in Greater Cairo. Cairo: Egypt Ministry of Health 
and Population, 2002.
43 Mosbah A, Nabiel Y. Helicobacter pylori, Chlamydiae pneumoniae and 
trachomatis as probable etiological agents of preeclampsia. 
J Matern Fetal Neonatal Med 2016; 29: 1607–12.
44 Mousa A. The association between Chlamydia trachomatis and 
cervical intra­epithelial neoplasia. Zagazig Med Assoc J 1990; 3: 41–46.
45 Nada AM, Hassan FM, Al­Azhary NH. Detection of Chlamydia 
trachomatis in patients with unexplained infertility: a case control 
study. Egypt J Med Microbiol 2015; 24: 35–38.
46 Sullam SA, Mahfouz AA, Dabbous NI, el­Barrawy M, el­Said MM. 
Reproductive tract infections among married women in 
Upper Egypt. East Mediterr Health J 2001; 7: 139–46.
47 Zaki SA. Prevalence of endocervical genital mycoplasmas and 
Chlamydia trachomatis in infertile, abortive and pregnant women in 
Alexandria. Bull Alex Fac Med 1989; 25: 1031–44.
48 Ahmadi A, Khodabandehloo M, Ramazanzadeh R, et al. 
The relationship between Chlamydia trachomatis genital infection 
and spontaneous abortion. J Reprod Infertil 2016; 17: 110–16.
49 Ahmadi MH, Mirsalehian A, Sadighi Gilani MA, Bahador A, Afraz K. 
Association of asymptomatic Chlamydia trachomatis infection with 
male infertility and the effect of antibiotic therapy in improvement of 
semen quality in infected infertile men. Andrologia 2018; 50: e12944.
50 Ahmadnia E, Kharaghani R, Maleki A, et al. Prevalence and 
associated factors of genital and sexually transmitted infections in 
married women of Iran. Oman Med J 2016; 31: 439–45.
51 Badami N, Salari MH. Rate of Chlamydia trachomatis, 
Mycoplasma hominis and Ureaplasma urealyticum in infertile females 
and control group. Iran J Public Health 2001; 30: 57–60.
52 Baghchesaraei H, Amini B, Hossaini M. Prevalence of infection 
with Neisseria gonorrhoeae and Chlamydia trachomatis in women 
visitors of gynecology and obstetrics clinics in Zanjan Province of 
Iran. Afr J Microbiol Res 2011; 5: 2447–50.
53 Bagheri S, Roghanian R, Golbang N, Golbang P, Esfahani MHN. 
Molecular evidence of Chlamydia trachomatis infection and its 
relation to miscarriage. Int J Fertil Steril 2018; 12: 152–56.
54 Behroozi R. Epidemiology of Chlamydia trachomatis infections in 
pregnant women of the hospitals of Tehran University of Medical 
Sciences. J Nurs Midwifery Sci 2001; 1: 14–20.
55 Chamani­Tabriz L, Jedi TM, Zeraati H, et al. A molecular survey of 
Chlamydia trachomatis infection in married women: a cross 
sectional study on 991 women. Tehran Univ Med J 2008; 66: 498–91.
56 Cheraghi M, Rahimi Z, Parsa S. Prevalence of cervical­vaginal 
infections in the pap­smear samples in Iran. Glob J Health Sci 2014; 
16: 201–06.
57 Dehghan ML, Aflatoonian A, Talebi AR, Eley A, Pacey AA. 
Relationship between Chlamydia trachomatis and Mycoplasma 
genitalium infection and pregnancy rate and outcome in Iranian 
infertile couples. Andrologia 2017; 49.
58 Goshayeshi L, Vahid Roudsari F, Ghazvini K, Nomani H, 
Amel Jamehdar S. Pilot prevalence of Chlamydia trachomatis by 
PCR in female infertile referred to study center of infertility in 
Mashhad. Iran South Med J 2015; 18: 92–99.
59 Haghighi Hasanabad M, Bahador A, Mohammadzadeh M, 
Haghighi F. Prevalence of Chlamydia trachomatis, Neisseria 
gonorrhoeae and Ureaplasma urealyticum in pregnant women of 
Sabzevar, Iran. Sex Transm Infect 2013; 89 (suppl 1): A233–34.
60 Jahromi AS, Farjam MR, Mogharrab F, et al. Chlamydia trachomatis 
in women with full­term deliveries and women with abortion. 
Am J Infect Dis 2010; 6: 66–69.
61 Javanmard D, Behravan M, Ghannadkafi M, Salehabadi A, Ziaee M, 
Namaei MH. Detection of Chlamydia trachomatis in pap smear 
samples from south Khorasan province of Iran. Int J Fertil Steril 
2018; 12: 31–36.
62 Joolayi F, Navidifar T, Jaafari RM, Amin M. Comparison of 
Chlamydia trachomatis infection among infertile and fertile women 
in Ahvaz, Iran: a case­control study. Int J Reprod Biomed (Yazd) 
2017; 15: 713–18.
63 Kajbaf MJ, Gholamnezhad A. Prevalence of Chlamydia trachomatis 
antigen and antibody in infertile women in Ahwaz. Iran Biomed J 
1998; 2: 45–48.
64 Kamyabi Z. The survey of anti Chlamydia antibody in infertile 
women undergoing diagnostic laparoscopy in Afzalipour medical 
centre, Kerman—Iran. Int J Gynaecol Obstet 2009; 107: S218.
65 Khezerdoust S, Hagh Elahi F, Roustaei S, Badami N, 
Naghizadeh MM, Jafarabadi M. Chlamydia trachomatis infection in 
pregnant women. J Reprod Infertil 2009; 10: 121–28.
66 Marashi SM, Moulana Z, Imani Fooladi AA, Mashhadi Karim M. 
Comparison of genital Chlamydia trachomatis infection incidence 
between women with infertility and healthy women in Iran using 
PCR and immunofluorescence methods. Jundishapur J Microbiol 
2014; 7: e9450.
67 Farhoudi B, Kamali K, Rajabpoor Z. Situation analysis of sexually 
transmitted infections in the Islamic Republic of Iran 2008. Tehran: 
Ministry of Health and Medical Education, 2008.
68 Meidani M. Frequency of Chlamydia trachomatis infection in 
asymptomatic males based on PCR in Tehran, Iran. 
Int Urogynecol J Pelvic Floor Dysfunct 2009; 20 (suppl 3): S460–61.
69 Mousavi A, Ramezanzadeh R, Farhadifar F, et al. Detection of 
Chlamydia trachomatis in fertile and infertile women in Sanandaj by 
PCR. Iran J Public Health 2014; 43: 63.
70 Pourabbas B, Rezaei Z, Mardaneh J, Shahian M, Alborzi A. 
Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae 
infections among pregnant women and eye colonization of their 
neonates at birth time, Shiraz, Southern Iran. BMC Infect Dis 2018; 
18: 477.
71 Rashidi BH, Chamani­Tabriz L, Haghollahi F, et al. Effects of 
Chlamydia trachomatis infection on fertility; a case­control study. 
J Reprod Infertil 2013; 14: 67–72.
72 Rohi E, Ghasemi K, Kahnemoii Agdam F. Incidence of 
non­gonococcal infection in childbearing and pregnant women in 
Ardabil. Int J Mol Clin Microbiol 2011; 1: 71–76.
73 Rostami MN, Rashidi BH, Aghsaghloo F, Nazari R. Comparison of 
clinical performance of antigen­based enzyme immunoassay (EIA) 
and major outer membrane protein (MOMP)­PCR for detection of 
genital Chlamydia trachomatis infection. Int J Reprod Biomed (Yazd) 
2016; 14: 411–20.
Articles
e1222 www.thelancet.com/lancetgh   Vol 7   September 2019
74 Safdari H, Safdari A, Tahaghoghi S, Yari A, Ghazvini K. 
Prevalence of Chlamydia trachomatis among women with genital 
infection in northeast of Iran in 2013. Iran J Obstet Gynecol Infertil 
2015; 18: 1–6.
75 Sattari M, Ghiami Rad M, Ghasemzadeh A, 
Mohammadoghli Reihan Z. Frequency of anti­Chlamydia 
trachomatis antibodies in infertile women referred to 
Tabriz Al­Zahra hospital. Int J Reprod Biomed (Yazd) 2017; 15: 17–20.
76 Sisakht AJ, Omidifar N, Mohamadkhani N, Karimpoorfard M, 
Kargar M, Shokripour M. Assessing the presence of Chlamydia 
trachomatis genome in pregnant women with spontaneous abortion 
using polymerase chain reaction method in Yasuj: first report from 
southwest of Iran. J Educ Health Promot 2017; 6: 45.
77 Yeganeh O, Jjeddi­Tehrani M, Yaghmaie F, et al. A survey on the 
prevalence of Chlamydia trachomatis and Mycoplasma genitalium 
infections in symptomatic and asymptomatic men referring to 
urology clinic of Labbafinejad Hospital, Tehran, Iran. 
Iran Red Crescent Med J 2013; 15: 340–44.
78 Zahirnia Z, Mansouri S, Saffari F, Mansouri G. Frequency of 
Chlamydia trachomatis, Mycoplasma genitalium, and Ureaplasma 
urealyticum isolated from vaginal samples of women in Kerman, 
Iran. Arch Clin Infect Dis 2018; 13: e65334.
79 Abdulkhudher NA, Yousif MG, Sadiq AM. Detection of 
immunological markers for Chlamydia trachomatis and Trichomonas 
vaginalis infection in women with obstetric complications in Najaf, 
Iraq. J Al-Qadisiyah Pure Sci 2014; 19: 1–25.
80 Abdul­Karim ET, Abdul­Muhymen N, Al­Saadie M. Chlamydia 
trachomatis and rubella antibodies in women with full­term deliveries 
and women with abortion in Baghdad. East Mediterr Health J 2009; 
15: 1407–11.
81 Abdullah FT. Study the role of Chlamydia trachomatis in ectopic 
pregnancy in Iraqi women. J Biotechnol Res Cent 2012; 6: 19–25.
82 Ahmed DW. Effects of interleukin­2 (IL­2) and interleukin­6 (IL­6) 
in recurrent spontaneous abortion (RSA). Iraqi J Pharm Sci 2008; 
17: 74–79.
83 Al­Hamdani SM, Shemran HA, Kadhim HS, Yasser H. Prevalence 
of anti­chlamydial immunoglobulins in pregnant women in 
Al­Kadhimiya Teaching Hospital. J Coll Teach 2010; 1: 59–70.
84 Al­Husseinei RK, Kadaem KM, Al­Janabi LA, Fathei MiM. 
ELFA and IFAT techniques to detect chlamydial infections in 
Baghdad women and its effect on the immunoglobulins level. 
J Facult Med 2009; 51: 192–97.
85 Ali MH, Al­Kazaz AA. Molecular detection of Chlamydia trachomatis 
infection among males with abnormal semen. Iraqi J Sci 2018; 
59: 2005–11.
86 Alkhafaf D. Prevalence of Chlamydia trachomatis in women of 
Al­Diwanyia city. J Babylon Univ 2013; 21: 1232–38.
87 Hwaid AH, Hasan A­RS, Al­Duliami AA. Seroprevalence of 
anti­C trachomatis IgG and IgM antibodies among pregnant women 
in Diyala province. J Facult Med Baghdad 2013; 55: 348–51.
88 Ismail MK, Ali AS. Evaluation of Chlamydia trachomatis antibodies 
in women with infertility. Al-Mustansiriyah J Sci 2012; 23: 21–28.
89 Mohammed NAM, Salman AH, Hasan FK. Chlamydia trachomatis 
and recurrent spontaneous abortion in Iraqi pregnant women. 
Iraqi J Med Sci 2012; 10: 42–46.
90 Mohammed IH, Al­Awadei SJ, Saadedin SMK. Molecular diagnosis 
of Chlamydia trachomatis in infertile Iraqi women using real 
time­PCR and comparison with other methods. Iraqi J Sci 2017; 
58: 1437–46.
91 Yahya M, Al­Siraj D. Study of genital Mycoplasma and Chlamydia 
trachomatis which presence in infertile males. Al-Taqani 2009; 
22: A23–31.
92 Abusarah EA, Awwad ZM, Charvalos E, Shehabi AA. Molecular 
detection of potential sexually transmitted pathogens in semen and 
urine specimens of infertile and fertile males. 
Diagn Microbiol Infect Dis 2013; 77: 283–86.
93 Al­Ramahi M, Mahafzah A, Saleh S, Fram K. Prevalence of 
Chlamydia trachomatis infection in infertile women at a university 
hospital in Jordan. East Mediterr Health J 2008; 14: 1148–54.
94 As’ad A. National AIDS program, final report sexually transmitted 
infections (STI) prevalence study, Jordan. 2004.
95 Awwad ZM, Al­Amarat AA, Shehabi AA. Prevalence of genital 
chlamydial infection in symptomatic and asymptomatic Jordanian 
patients. Int J Infect Dis 2003; 7: 206–09.
96 Mahafzah AM, Al­Ramahi MQ, Asa’d AM, El­Khateeb MS. 
Prevalence of sexually transmitted infections among sexually active 
Jordanian females. Sex Transm Infect 2008; 35: 607–10.
97 Jordan Ministry of Health. Prevalence of reproductive tract infections 
in women attending selected urban OB/GYN clinics in Jordan. 2004.
98 Al­Awadhi R, Al­Shaheen A, Al­Juwaiser A, George SS, Sharma P, 
Kapila K. Prevalence of infectious organisms observed in cervical 
smears between 1997–2014 at Mubarak Al­Kabeer Hospital, Kuwait. 
Sultan Qaboos Univ Med J 2018; 18: e324–28.
99 Al­Sweih NA, Khan S, Rotimi VO. Prevalence of Chlamydia 
trachomatis and Neisseria gonorrhoeae among asymptomatic women 
attending the Capital Health region clinics in Kuwait. 
Sex Transm Infect 2011; 38: 793–97.
100 Al­Sweih NA, Al­Fadli AH, Omu AE, Rotimi VO. Prevalence of 
Chlamydia trachomatis, Mycoplasma hominis, Mycoplasma genitalium, 
and Ureaplasma urealyticum infections and seminal quality in 
infertile and fertile men in Kuwait. J Andrology 2012; 33: 1323–29.
101 Deeb ME, Awwad J, Yeretzian JS, Kaspar HG. Prevalence of 
reproductive tract infections, genital prolapse, and obesity in a rural 
community in Lebanon. Bull World Health Organ 2003; 81: 639–45.
102 Hancali A, Bellaji B, Jennane S, et al. Trend of STIs prevalence 
among women and men in Morocco between 1999 to 2011. 
Sex Transm Infect 2015; 91: A155.
103 Hulstein SH, Matser A, Alberts CJ, et al. Differences in Chlamydia 
trachomatis seroprevalence between ethnic groups cannot be fully 
explained by socioeconomic status, sexual healthcare seeking 
behavior or sexual risk behavior: a cross­sectional analysis in the 
HEalthy LIfe in an Urban Setting (HELIUS) study. BMC Infect Dis 
2018; 18: 612.
104 Morocco Ministry of Health. Etude de prévalence IST chez les 
femmes consultantes en SMI/PF à la Wilaya de Rabat, Rapport 
final, Programme National de lutte contre les IST/SIDA. Rabat: 
Morocco Ministry of Health, 2001.
105 Abu­Raddad LJ. Additional data points from the Middle East and 
North Africa HIV/AIDS Epidemiology Synthesis Project database. 
Tehran: Infectious Disease Epidemiology Group, 2017.
106 Radouani F, Takourt B, Ibrahimy S, Sekkat S, Guinet R, 
Benslimane A. Contribution of Chlamydia trachomatis infection to 
infertility. Rev Fr Gynecol Obstet 1998; 93: 442–46.
107 Takourt B, Radouani F, Benchekroun A, et al. Seroprevalence of 
Chlamydia trachomatis infection in STD consultants in Morocco. 
Bull Soc Pathol Exot 1995; 88: 194–98.
108 Mir AM, Wajid A, Reichenbach L, Khan M. STI prevalence and 
associated factors among urban men in Pakistan. Sex Transm Infect 
2009; 85: 199–200.
109 Wasti S, Ashfaq MK, Ishaq R, Hamid R. Prevalence of chlamydial 
infection in females attending antenatal and family planning clinics 
in Karachi Pakistan. Aust N Z J Obstet Gynaecol 1997; 37: 462–65.
110 Al­Thani A, Abdul­Rahim H, Alabsi E, et al. Prevalence of 
Chlamydia trachomatis infection in the general population of 
women in Qatar. Sex Transm Infect 2013; 89 (suppl 3): iii57–60.
111 Alzahrani AJ, Obeid OE, Hassan MI, Almulhim AA. Screening of 
pregnant women attending the antenatal care clinic of a tertiary 
hospital in eastern Saudi Arabia for Chlamydia trachomatis and 
Neisseria gonorrhoeae infections. Indian J Sex Transm Dis AIDS 2010; 
31: 81–86.
112 Awad NS, Said MM, Mohamed AA, El­Tarras AE. Detection of some 
sexually transmitted bacterial infection using molecular genetic 
technique. World J Med Sci 2013; 9: 142–46.
113 Bashi SA. Chlamydial infection in Riyadh, Saudi Arabia: 
a sero­epidemiological survey. Saudi Med J 1987; 4: 387–90.
114 Ghazi HO, Daghestani MH, Mohamed MF. Seropositivity of 
Chlamydia trachomatis among Saudi pregnant women in Makkah. 
J Family Community Med 2006; 13: 61–64.
115 Hossain A. Serologic diagnosis of Chlamydia trachomatis infections. 
Int J Gynaecol Obstet 1988; 27: 377–80.
116 Kamel RM. Screening for Chlamydia trachomatis infection among 
infertile women in Saudi Arabia. Int J Womens Health 2013; 
5: 277–84.
117 Massoud M, Noweir A, Salah M, Saleh WA. Chlamydial infection in 
Riyadh, Saudi Arabia. J Egypt Public Health Assoc 1991; 66: 411–19.
118 Ismail SO, Ahmed HJ, Jama MA, et al. Syphilis, gonorrhoea and 
genital chlamydial infection in a Somali village. Genitourin Med 
1990; 66: 70–75.
Articles
www.thelancet.com/lancetgh   Vol 7   September 2019 e1223
119 Nur YA, Groen J, Elmi AM, Ott A, Osterhaus AD. Prevalence of 
serum antibodies against bloodborne and sexually transmitted agents 
in selected groups in Somalia. Epidemiol Infect 2000; 124: 137–41.
120 WHO. Central South: the 2004 first national second generation 
HIV/AIDS/STI sentinel surveillance survey. Geneva: World Health 
Organization, 2005a.
121 WHO. The 2004 first national second generation HIV/AIDS/STI 
sentinel surveillance survey. Geneva: World Health Organization, 
2005b.
122 Ahmed MA, Hassan NG, Omer ME, Rostami A, Rayis DA, Adam I. 
Helicobacter pylori and Chlamydia trachomatis in Sudanese women 
with preeclampsia. J Matern Fetal Neonatal Med 2018; published 
online Oct 14. DOI:10.1080/14767058.2018.1536738.
123 Almroth L, Elmusharaf S, El Hadi N, et al. Primary infertility after 
genital mutilation in girlhood in Sudan: a case­control study. Lancet 
2005; 366: 385–91.
124 Ortashi OM, El Khidir I, Herieka E. Prevalence of HIV, syphilis, 
Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis 
and candidiasis among pregnant women attending an antenatal 
clinic in Khartoum, Sudan. J Obstet Gynaecol 2004; 24: 513–15.
125 Alkayer SM, Yazji HN, Khamis A. The prevalence of serum IgG 
antibody to Chlamydia trachomatis in infertile women at the 
university hospital, Syria. Res J Pharm Technol 2017; 10: 1373–75.
126 Ghazal­Aswad S, Badrinath P, Osman NA, Abdul­Khalik S, 
Raasclou T. Is there a correlation between vaginal chlamydia 
infection and cervical smear abnormalities? A community­based 
study in the Al­Ain district, United Arab Emirates. 
J Obstet Gynaecol Res 2006; 32: 63–67.
127 Explorable. Non­probability sampling. 2009. https://explorable.
com/non­probability­sampling (accessed April 10, 2019).
128 Glen S. Probability sampling: definition, types, advantages and 
disadvantages. 2015. https://www.statisticshowto.datasciencecentral.
com/probability­sampling/ (accessed April 10, 2019).
129 Johnston LG. Respondent driven sampling (RDS). 2014. 
http://www.lisagjohnston.com/respondent­driven­sampling 
(accessed April 10, 2019).
130 Darougar S, Aramesh B, Gibson JA, Treharne JD, Jones BR. 
Chlamydial genital infection in prostitutes in Iran. Br J Vener Dis 
1983; 59: 53–55.
131 Kassaian N, Ataei B, Yaran M, Babak A, Shoaei P, Ataie M. 
HIV and other sexually transmitted infections in women with 
illegal social behavior in Isfahan, Iran. Adv Biomed Res 2012; 1: 5.
132 Kazerooni PA, Motazedian N, Motamedifar M, et al. 
The prevalence of human immunodeficiency virus and sexually 
transmitted infections among female sex workers in Shiraz, 
south of Iran: by respondent­driven sampling. Int J STD AIDS 
2014; 25: 155–61.
133 Mirzazadeh ASM, Khajehkazemi R, Hosseini Hooshyar S, et al. 
HIV and sexually transmitted infections among female sex workers 
in Iran: findings from the 2010 and 2015 national surveillance 
surveys. International AIDS Conference; Durban, South Africa; 
July 18–22, 2016.
134 Bellaji B, Hancali A, Jennane S, et al. Prevalence of Chlamydia 
trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in 
female sex workers in Morocco. Sex Transm Infect 2017; 
93 (suppl 2): A100.
135 Morocco Ministry of Health. Etude de prévalence des IST chez les 
femmes qui consultent pour pertes vaginales et/ou douleurs du bas 
ventre. Rabat: Morocco Ministry of Health, 2008.
136 Morocco Ministry of Health. HIV integrated behavioral and biological 
surveillance surveys. Rabat: Morocco Ministry of Health, 2011.
137 Morocco Ministry of Health. Integrated behavioral and biological 
surveillance survey among men who have sex with men (MSM) in 
Agadir, Casablanca, Marrakech, and Tangier. Rabat: Morocco Ministry 
of Health, 2015.
138 Hawkes S, Collumbien M, Platt L, et al. HIV and other sexually 
transmitted infections among men, transgenders and women selling 
sex in two cities in Pakistan: a cross­sectional prevalence survey. 
Sex Transm Infect 2009; 85 (suppl 2): ii8–16.
139 Khan MS, Unemo M, Zaman S, Lundborg CS. HIV, STI prevalence 
and risk behaviours among women selling sex in Lahore, Pakistan. 
BMC Infect Dis 2011; 11: 119.
140 Osama M. Rate of STI among selected MSM and transgenders in 
5 cities of Pakistan. Sex Transm Infect 2017; 93 (suppl 2): A18.
141 Rehan N, Bokhari A, Nizamani NM, et al. National study of 
reproductive tract infections among high risk groups of Lahore and 
Karachi. J Coll Physicians Surg Pak 2009; 19: 228–31.
142 Znazen A, Frikha­Gargouri O, Berrajah L, et al. Sexually transmitted 
infections among female sex workers in Tunisia: high prevalence of 
Chlamydia trachomatis. Sex Transm Infect 2010; 86: 500–05.
143 Abdel Aleem H, Moubasher AED, Abdel Megeed E. Seroprevalence 
of Chlamydia trachomatis among infertile couples in Assiut. 
Ain-Shams Med J 1996; 47: 759–67.
144 Abdella RM, Abdelmoaty HI, Elsherif RH, et al. Screening for 
Chlamydia trachomatis in Egyptian women with unexplained 
infertility, comparing real­time PCR techniques to standard 
serology tests: case control study. BMC Womens Health 2015; 15: 45.
145 Azab H, Hassouna AA. Evaluation of clinical findings and 
chlamydia antibody titre as predictors of tubal factor infertility. 
Med J Cairo Univ 2008; 76: 171–75.
146 Elkayal NM, Mahmoud NF, Abdalla S. Detection of Chlamydia 
trachomatis and Neisseria gonorrhoeae in Egyptian women suffering 
from infertility. Adv Microbiol 2015; 5: 769–79.
147 El Sayed AF, Al Bakry MM, Zaitoun MM, AbouTalib AF. 
Comparative study of hysterosalpingography and chlamydia 
antibody testing in predicting tubal factor infertility. 
Ain-Shams Med J 1997; 48: 815–25.
148 Inhorn MC, Buss KA. Infertility, infection, and iatrogenesis in 
Egypt: the anthropological epidemiology of blocked tubes. 
Med Anthropol 1993; 15: 217–44.
149 Makled AK, Elkady OS, Swedan KH, Sammour HM, Mohamed EA. 
Relationship between serum Chlamydia trachomatis antibody titer 
and tubal block in infertile Egyptian women. Middle East Fertil Soc J 
2013; 18: 38–41.
150 Sadek S, Abo Gabal A, El Hefnawi N. Chlamydial infection and 
sperm antibodies. New Egypt J Med 1993; 8: 1461–63.
151 Siam EM, Hefzy EM. The relationship between antisperm 
antibodies prevalence and genital Chlamydia trachomatis infection 
in women with unexplained infertility. Middle East Fertil Soc J 2012; 
17: 93–100.
152 Younis HA, El Sayed SA, Abdel Wahab A, Ayoub AA. Detection of 
Chlamydia trachomatis DNA by polymerase chain reaction in urine 
of women with tubal infertility as diagnosed by 
hysterosalpingography and laparoscopy. Sci J Al-Azhar Med Fac 
2000; 21: 731–44.
153 Zaitun MM, Zaitoun A. Chlamydia trachomatis infection in cases of 
infertility due to tubal factor: a serological study. Zagazig Med Assoc J 
1990; 3: 125–33.
154 Zytoon MM. The role of Chlamydia trachomatis infection in female 
infertility. New Egypt J Med 1994; 11: 938–42.
155 Golshani M, Eslami G, Ghobadloo SM, et al. Detection of 
Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma 
urealyticum by multiplex PCR in semen sample of infertile men. 
Iran J Public Health 2007; 36: 50–57.
156 Hajikhani B, Motallebi T, Norouzi J, et al. Classical and molecular 
methods for evaluation of Chlamydia trachomatis infection in women 
with tubal factor infertility. J Reprod Infertil 2013; 14: 29–33.
157 Kalantar SM, Kazemi MJ, Sheikhha MH, Aflatoonian A, 
Kafilzadeh F. Detection of Chlamydia trachomatis infection in female 
partners of infertile couples. Iran J Fertil Steril 2007; 1: 79–84.
158 Mansour Ghanaie M. Relative frequency of Chlamydia trachomatis 
infection in infertile women. Int J Fertil Steril 2014; 8: 110.
159 Moazenchi M, Totonchi M, Salman Yazdi R, et al. The impact of 
Chlamydia trachomatis infection on sperm parameters and male 
fertility: a comprehensive study. Int J STD AIDS 2018; 29: 466–73.
160 Nan Bakhsh F, Tarvati MR, Yekta Z, Gol MS, Mehrzad Sadaghiani M, 
Shokri S. Evaluation of the prognostic value of Chlamydia trachomatis 
antibody testing (CAT), HSG and laparoscopy in predicting tubal 
factor infertility (TFI) in Motahary Hospital, Urmiyah, Iran. 
Med J Tabriz Univ Med Sci 2008; 30: 119–25.
161 Nikbakht R, Saharkhiz N, Ghalambor Dezfouli F. Comparison of 
level of antibodies against Chlamydia trachomatis in infertile women 
due to tubal factors and fertile women. 
J Shahid Sadoughi Univ Med Sci Health Serv 2008; 16: 10–15.
162 Peivandi S, Moslemizadeh N, Gharajeh S, Ajami A. The role of 
Chlamydia trachomatis IgG antibody testing in predicting tubal 
factor infertility in northern Iran. Int J Fertil Steril 2009; 
3: 143–48.
Articles
e1224 www.thelancet.com/lancetgh   Vol 7   September 2019
163 Rashidi B, Shahrokh Tehraninezhad E, Alaie F. Prevalence of 
antichlamydia antibody status in infertile patients. Int J Fertil Steril 
2007; 1: 15–18.
164 Sadrpour P, Bahador A, Asgari S, Bagheri R, Chamani­Tabriz L. 
Detection of Chlamydia trachomatis and Mycoplasma genitalium in 
semen samples of infertile men using multiplex PCR. 
Tehran Univ Med J 2013; 70: 623–29.
165 Siahkali AP, Amini K. Identification of herpes simplex virus, 
Chlamydia trachomatis, and Mycoplasma genitalium in infertile 
seminal fluid samples using multiplex­PCR in Kerman province, 
Iran (2016). Iran J Obstet Gynecol Infertil 2018; 21: 69–74.
166 Abid A­AJ, Al­Zwaid AJ. Chlamydial antibodies, pro­inflammatory 
cytokines and bacterial significance among infertile women. 
Med J Babylon 2015; 12: 943–47.
167 Ahmed ST. Detection of Chlamydia trachomatis using polymerase 
chain reaction (PCR). Al-Mustansiriyah J Sci 2012; 23: 35–42.
168 Al­Kattan SAA­K, Mohammed RA. Laparoscopic finding and 
Chlamydia trachomatis infection in infertile women. Med J Tikrit 
2013; 19: 315–24.
169 Dawood SD. Chlamydia trachomatis in Iraqi women with infertility. 
Iraqi J Biotechnol 2011; 10: 89–94.
170 Al Subhi T, Al Jashnmi RN, Al Khaduri M, Gowri V. Prevalence of 
tubal obstruction in the hysterosalpingogram of women with 
primary and secondary infertility. J Reprod Infertil 2013; 
14: 214–16.
171 Qayum M, Khalid­bin­Saleem M. Prevalence of Chlamydia 
trachomatis among asymptomatic women. J Ayub Med Coll Abbottabad 
2013; 25: 28–30.
172 Al­Hindi A, Al­Helou T, Al­Helou Y. Seroprevalence of Toxoplasma 
gondii, cytomegalovirus, rubella virus and Chlamydia trachomatis 
among infertile women attending in vitro fertilization center, 
Gaza strip, Palestine. J Egypt Soc Parasitol 2010; 40: 451–58.
173 Abdul Jabbar HS. Chlamydial infection in Saudi infertile patients. 
Bahrain Med Bull 1990; 12: 4–7.
174 Alfarraj DA, Somily AM, Alssum RM, Abotalib ZM, El­Sayed AA, 
Al­Mandeel HH. The prevalence of Chlamydia trachomatis infection 
among Saudi women attending the infertility clinic in Central 
Saudi Arabia. Saudi Med J 2015; 36: 61–66.
175 Sabra SMM, Al­Harbi MS. An influential relationship of seminal 
fluid microbial infections and infertility, Taif Region, KSA. 
World J Med Sci 2014; 10: 32–37.
176 Gdoura R, Daoudi F, Bouzid F, et al. Detection of Chlamydia 
trachomatis in semen and urethral specimens from male members 
of infertile couples in Tunisia. Eur J Contracept Reprod Health Care 
2001; 6: 14–20.
177 Gdoura R, Keskes­Ammar L, Bouzid F, Eb F, Hammami A, Orfila J. 
Chlamydia trachomatis and male infertility in Tunisia. 
Eur J Contracept Reprod Health Care 2001; 6: 102–07.
178 Gdoura R, Kchaou W, Ammar­Keskes L, et al. Assessment of 
Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma 
parvum, Mycoplasma hominis, and Mycoplasma genitalium in semen 
and first void urine specimens of asymptomatic male partners of 
infertile couples. J Andrology 2008; 29: 198–206.
179 Sellami H, Znazen A, Sellami A, et al. Molecular detection of 
Chlamydia trachomatis and other sexually transmitted bacteria in 
semen of male partners of infertile couples in Tunisia: the effect on 
semen parameters and spermatozoa apoptosis markers. PLoS One 
2014; 9: e98903.
180 Ahmadi A, Khodabandehloo M, Ramazanzadeh R, et al. 
The relationship between Chlamydia trachomatis genital infection 
and spontaneous abortion. J Reprod Infertil 2016; 17: 110–16.
181 Bagheri S, Roghanian R. Evaluation of Chlamydia trachomatis 
incidence in women who had abortion in Isfahan. 
Iran J Public Health 2014; 43: 63.
182 Massiha A, Khoshkholgh Pahlaviani MRM, Sedighi Kasmaie P, 
Vand Yousefi J. Study of the reasons of infectious abortions in the 
subjects who approached Kamali Hospital, Karaj in Iran. 
J Reprod Med Endocrinol 2010; 7: 346.
183 Salari MH, Badami N. The rate of Chlamydia trachomatis, 
Mycoplasma hominis and Ureaplasma urealyticum in females and 
habitual abortion. ACTA Medica Iranica 2002; 40: 79–82.
184 Al­Nuaimy WA, Al­Jandeel T. Immunological and molecular study 
of Chlamydia trachomatis as causative agent of abortion in 
Al­Muthanna province. Iraqi J Vet Sci 2018; 42: 99–104.
185 Salman YJ. Chlamydia trachomatous antibodies cross reaction with 
seropositive Toxoplasma gondii and cytomegalovirus among women 
with abortion and outcomes of congenital abnormalities in Kirkuk 
City. Tikrit J Pure Sci 2016; 21: 1–5.
186 Harbord RM, Higgins JPT. Meta­regression in Stata. Stata J 2008; 
8: 493–519.
187 Dargham SR, Nasrallah GK, Al­Absi ES, et al. Herpes simplex virus 
type 2 seroprevalence among different national populations of 
Middle East and north African men. Sex Transm Infect 2018; 
45: 482–87.
188 Abu­Raddad LJ, Schiffer JT, Ashley R, et al. HSV­2 serology can be 
predictive of HIV epidemic potential and hidden sexual risk behavior 
in the Middle East and north Africa. Epidemics 2010; 2: 173–82.
189 Vaccarella S, Bruni L, Seoud M. Burden of human papillomavirus 
infections and related diseases in the extended Middle East and 
north Africa region. Vaccine 2013; 31 (suppl 6): G32–44.
190 Rowley J, Hoorn SV, Korenromp E, et al. Chlamydia, gonorrhoea, 
trichomoniasis and syphilis: global prevalence and incidence 
estimates, 2016. Bull World Health Organ 2019, published online 
July 4. ID:BLT.18.218651.
191 Sonnenberg P, Clifton S, Beddows S, et al. Prevalence, risk factors, 
and uptake of interventions for sexually transmitted infections in 
Britain: findings from the National Surveys of Sexual Attitudes and 
Lifestyles (Natsal). Lancet 2013; 382: 1795–806.
192 CDC, National Center for Health Statistics. National health and 
nutrition examination survey data, 1999–2014. https://wwwn.cdc.
gov/nchs/nhanes/continuousnhanes/default.aspx (accessed 
Sept 25, 2017).
193 Redmond SM, Alexander­Kisslig K, Woodhall SC, et al. 
Genital chlamydia prevalence in Europe and non­European high 
income countries: systematic review and meta­analysis. PLoS One 
2015; 10: e0115753.
194 Toomey KE, Rafferty MP, Stamm WE. Unrecognized high 
prevalence of Chlamydia trachomatis cervical infection in an isolated 
Alaskan Eskimo population. JAMA 1987; 258: 53–56.
195 Walsh MS, Hope E, Isaia L, et al. Prevalence of Chlamydia 
trachomatis infection in Samoan women aged 18 to 29 and 
assessment of possible risk factors: a community­based study. 
Trans R Soc Trop Med Hyg 2015; 109: 245–51.
196 Stamm WE. Chlamydia trachomatis infections of the adult. 
In: Holmes KK, Sparling FP, Stamm WE, et al, eds. Sexually 
transmitted diseases, 4th edn. New York: McGraw Hill Medical, 
2008: 575–93.
197 Molano M, Meijer CJ, Weiderpass E, et al. The natural course of 
Chlamydia trachomatis infection in asymptomatic Colombian 
women: a 5­year follow­up study. J Infect Dis 2005; 191: 907–16.
198 Heijne JC, Herzog SA, Althaus CL, Low N, Kretzschmar M. 
Case and partnership reproduction numbers for a curable sexually 
transmitted infection. J Theor Biol 2013; 331: 38–47.
199 Omori R, Chemaitelly H, Althaus CL, Abu­Raddad LJ. 
Does infection with Chlamydia trachomatis induce long­lasting 
partial immunity? Insights from mathematical modelling. 
Sex Transm Infect 2019; 95: 115–21.
200 Al­Mutairi N, Joshi A, Nour­Eldin O, Sharma AK, El­Adawy I, 
Rijhwani M. Clinical patterns of sexually transmitted diseases, 
associated sociodemographic characteristics, and sexual practices in 
the Farwaniya region of Kuwait. Int J Dermatol 2007; 46: 594–99.
201 Ismail SO, Ahmed HJ, Grillner L, Hederstedt Issa BA, Bygdeman S. 
Sexually transmitted diseases in men in Mogadishu, Somalia. 
Int J STD AIDS 1990; 1: 102–06.
202 Faisel A, Cleland J. Migrant men: a priority for HIV control in 
Pakistan? Sex Transm Infect 2006; 82: 307–10.
203 Mumtaz GR, Riedner G, Abu­Raddad LJ. The emerging face of the 
HIV epidemic in the Middle East and north Africa. 
Curr Opin HIV AIDS 2014; 9: 183–91.
204 Inhorn MC. Quest for conception: gender, infertility and Egyptian 
medical traditions. Philadelphia, PA: University of Pennsylvania 
Press, 1994.
205 Zurayk H, Sholkamy H, Younis N, Khattab H. Women’s health 
problems in the Arab world: a holistic policy perspective. 
Int J Gynaecol Obstet 1997; 58: 13–21.
206 Eggert­Kruse W, Buhlinger­Gopfarth N, Rohr G, et al. Antibodies to 
Chlamydia trachomatis in semen and relationship with parameters 
of male fertility. Hum Reprod 1996; 11: 1408–17.
Articles
www.thelancet.com/lancetgh   Vol 7   September 2019 e1225
207 Eggert­Kruse W, Weltin M, Strowitzki T. Are chlamydial 
lipopolysaccharide­directed antibodies in seminal plasma or serum 
clinically significant during investigation of male infertility? Urology 
2011; 77: 1101–06.
208 Dietrich W, Rath M, Stanek G, Apfalter P, Huber JC, Tempfer C. 
Multiple site sampling does not increase the sensitivity of 
Chlamydia trachomatis detection in infertility patients. Fertil Steril 
2010; 93: 68–71.
209 Miron N, Socolov D, Mares M, et al. Bacteriological agents which 
play a role in the development of infertility. 
Acta Microbiol Immunol Hung 2013; 60: 41–53.
210 Faour M. Fertility policy and family planning in the Arab countries. 
Stud Fam Plann 1989; 20: 254–63.
211 Rashad H, Khadr Z. The demography of the Arab region: 
new challenges and opportunities. In: Human capital: population 
economics in the Middle East. Sirageldin I, ed. London: I B Tauris, 
2002: 37–49.
212 Rashad H, Osman M. Nuptiality in Arab countries: changes and 
implications. In: Cairo papers in social science. Hopkins NS, ed. 
Cairo: American University in Cairo Press, 2003; 20–50.
213 Bristow CC, Mathelier P, Ocheretina O, et al. Chlamydia 
trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis 
screening and treatment of pregnant women in Port­au­Prince, 
Haiti. Int J STD AIDS 2017; 28: 1130–34.
214 Cabeza J, Garcia PJ, Segura E, et al. Feasibility of Chlamydia 
trachomatis screening and treatment in pregnant women in Lima, 
Peru: a prospective study in two large urban hospitals. 
Sex Transm Infect 2015; 91: 7–10.
215 Joseph Davey DL, Shull HI, Billings JD, Wang D, Adachi K, 
Klausner JD. Prevalence of curable sexually transmitted infections 
in pregnant women in low­ and middle­income countries from 
2010 to 2015: a systematic review. Sex Transm Infect 2016; 
43: 450–58.
216 Nguyen M, Le GM, Nguyen HTT, Nguyen HD, Klausner JD. 
Acceptability and feasibility of sexually transmissible infection 
screening among pregnant women in Hanoi, Vietnam. Sex Health 
2019; 16: 133–38.
217 Wynn A, Ramogola­Masire D, Gaolebale P, et al. Prevalence and 
treatment outcomes of routine Chlamydia trachomatis, Neisseria 
gonorrhoeae and Trichomonas vaginalis testing during antenatal care, 
Gaborone, Botswana. Sex Transm Infect 2018; 94: 230–35.
218 Syred J, Engler B, Campbell L, Baraitser P, Sheringham J. 
Exploration of gender differences of Chlamydia trachomatis 
infection amongst young people reveals limitations of using sexual 
histories to assess risk in high­prevalence areas. Int J STD AIDS 
2014; 25: 564–70.
219 Horner PJ, Wills GS, Reynolds R, et al. Effect of time since 
exposure to Chlamydia trachomatis on chlamydia antibody detection 
in women: a cross­sectional study. Sex Transm Infect 2013; 
89: 398–403.
220 Hocking JS, Temple­Smith M, Guy R, et al. Population effectiveness 
of opportunistic chlamydia testing in primary care in Australia: 
a cluster­randomised controlled trial. Lancet 2018; 392: 1413–22.
221 WHO. Strategies and laboratory methods for strengthening 
surveillance of sexually transmitted infections 2012. Geneva: 
World Health Organization, 2012. http://www.who.int/
reproductivehealth/publications/rtis/9789241504478/en/ (accessed 
Aug 9, 2014).
222 Bozicevic I, Riedner G, Calleja JM. HIV surveillance in MENA: 
recent developments and results. Sex Transm Infect 2013; 
89 (suppl 3): iii11–16.
223 Ayoub HH, Awad SF, Abu­Raddad LJ. Use of routine HIV testing 
data for early detection of emerging HIV epidemics in high­risk 
subpopulations: a concept demonstration study. Infect Dis Model 
2018; 3: 373–84.
224 Reintjes R, Wiessing L. 2nd­generation HIV surveillance and 
injecting drug use: uncovering the epidemiological ice­berg. 
Int J Public Health 2007; 52: 166–72.
225 Hessini L. Abortion and Islam: policies and practice in the 
Middle East and north Africa. Reprod Health Matters 2007; 15: 75–84.
226 Shapiro GK. Abortion law in Muslim­majority countries: 
an overview of the Islamic discourse with policy implications. 
Health Policy Plan 2014; 29: 483–94.
